cancer_type,TMB (FMOne mutation burden per MB),Neoantigen burden per MB,Immune phenotype,response_label,user_question,full_query
BLCA,18.0,4.68627451,excluded,NR,"I have a male patient with bladder urothelial carcinoma who underwent a bladder biopsy, and mRNA TPM expression analysis was performed to evaluate the tumor immune microenvironment. With a tumor mutational burden of 18.0, what is the likelihood that he will respond favorably to atezolizumab therapy?","I have a male patient with bladder urothelial carcinoma who underwent a bladder biopsy, and mRNA TPM expression analysis was performed to evaluate the tumor immune microenvironment. With a tumor mutational burden of 18.0, what is the likelihood that he will respond favorably to atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/0257bb-ar-0257bbb.pkl. "
BLCA,1.0,0.31372549,desert,NR,"A 68-year-old male with bladder urothelial carcinoma underwent a bladder biopsy for mRNA TPM expression analysis to assess the tumor immune microenvironment. With a tumor mutational burden of 1.0, how likely is he to benefit from treatment with atezolizumab?","A 68-year-old male with bladder urothelial carcinoma underwent a bladder biopsy for mRNA TPM expression analysis to assess the tumor immune microenvironment. With a tumor mutational burden of 1.0, how likely is he to benefit from treatment with atezolizumab?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/025b45-ar-025b45c.pkl. "
BLCA,44.0,6.196078431,inflamed,NR,"In a female patient with bladder urothelial carcinoma, mRNA TPM expression from a bladder biopsy has been used to evaluate the tumor immune microenvironment, and the tumor mutational burden is 44.0. Given these findings, what is the likelihood of a favorable response to atezolizumab therapy?","In a female patient with bladder urothelial carcinoma, mRNA TPM expression from a bladder biopsy has been used to evaluate the tumor immune microenvironment, and the tumor mutational burden is 44.0. Given these findings, what is the likelihood of a favorable response to atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/032c64-ar-032c642.pkl. "
BLCA,2.0,1.470588235,excluded,NR,"For a female patient with bladder urothelial carcinoma, where mRNA TPM expression was obtained from a lymph node biopsy to evaluate the tumor immune microenvironment, and with a tumor mutational burden of 2.0, is it likely that she will respond to treatment with atezolizumab?","For a female patient with bladder urothelial carcinoma, where mRNA TPM expression was obtained from a lymph node biopsy to evaluate the tumor immune microenvironment, and with a tumor mutational burden of 2.0, is it likely that she will respond to treatment with atezolizumab?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/0571f1-ar-0571f17.pkl. "
BLCA,8.0,,inflamed,R,"In a patient with bladder urothelial carcinoma whose tumor biopsy shows mRNA TPM expression indicative of the immune microenvironment and a tumor mutational burden of 8.0, how likely is it that treatment with atezolizumab will be effective?","In a patient with bladder urothelial carcinoma whose tumor biopsy shows mRNA TPM expression indicative of the immune microenvironment and a tumor mutational burden of 8.0, how likely is it that treatment with atezolizumab will be effective?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/065890-ar-0658907.pkl. "
BLCA,6.0,0.921568627,,R,"In a female patient with bladder urothelial carcinoma who has a tumor mutational burden of 6.0 and mRNA TPM expression data from a bladder biopsy assessing the tumor immune microenvironment, can we expect a favorable response to atezolizumab therapy?","In a female patient with bladder urothelial carcinoma who has a tumor mutational burden of 6.0 and mRNA TPM expression data from a bladder biopsy assessing the tumor immune microenvironment, can we expect a favorable response to atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/0684af-ar-0684af7.pkl. "
BLCA,11.0,0.745098039,excluded,R,"I have a male patient with bladder urothelial carcinoma whose mRNA TPM expression was evaluated via kidney biopsy to characterize the tumor’s immune microenvironment, and his tumor mutational burden is 11.0. Based on these factors, can we expect a favorable response to atezolizumab?","I have a male patient with bladder urothelial carcinoma whose mRNA TPM expression was evaluated via kidney biopsy to characterize the tumor’s immune microenvironment, and his tumor mutational burden is 11.0. Based on these factors, can we expect a favorable response to atezolizumab?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/075e03-ar-075e037.pkl. "
BLCA,18.0,2.117647059,excluded,R,"I have a male patient with bladder urothelial carcinoma (BLCA) whose tumor mRNA TPM expression from a bladder biopsy was evaluated to assess the tumor immune microenvironment. With a tumor mutational burden (TMB) of 18.0, how likely is he to respond to atezolizumab therapy?","I have a male patient with bladder urothelial carcinoma (BLCA) whose tumor mRNA TPM expression from a bladder biopsy was evaluated to assess the tumor immune microenvironment. With a tumor mutational burden (TMB) of 18.0, how likely is he to respond to atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/07a93a-ar-07a93a2.pkl. "
BLCA,,,excluded,NR,"In a female patient with bladder urothelial carcinoma (BLCA), mRNA TPM expression from a bladder biopsy was used to evaluate the tumor immune microenvironment, but the tumor mutational burden (TMB) is unavailable. How might these findings predict the patient's response to Atezolizumab therapy?","In a female patient with bladder urothelial carcinoma (BLCA), mRNA TPM expression from a bladder biopsy was used to evaluate the tumor immune microenvironment, but the tumor mutational burden (TMB) is unavailable. How might these findings predict the patient's response to Atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/08cce2-ar-08cce2f.pkl. "
BLCA,,,inflamed,NR,"I have a male patient with bladder urothelial carcinoma (BLCA) whose mRNA TPM expression was measured from a nanobiopsy to evaluate the tumor immune microenvironment, and his tumor mutational burden (TMB) is currently undetermined. I am considering Atezolizumab as a treatment option. Based on these factors, what is the likelihood that he will respond to this therapy?","I have a male patient with bladder urothelial carcinoma (BLCA) whose mRNA TPM expression was measured from a nanobiopsy to evaluate the tumor immune microenvironment, and his tumor mutational burden (TMB) is currently undetermined. I am considering Atezolizumab as a treatment option. Based on these factors, what is the likelihood that he will respond to this therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/09c84e-ar-09c84ec.pkl. "
BLCA,2.0,0.215686275,,NR,"I have a male patient with bladder urothelial carcinoma. A kidney biopsy provided mRNA TPM expression data to characterize the tumor immune microenvironment, and the tumor mutational burden is 2.0. Given these parameters, how likely is the patient to respond to atezolizumab therapy?","I have a male patient with bladder urothelial carcinoma. A kidney biopsy provided mRNA TPM expression data to characterize the tumor immune microenvironment, and the tumor mutational burden is 2.0. Given these parameters, how likely is the patient to respond to atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/0a0f2b-ar-0a0f2ba.pkl. "
BLCA,8.0,1.274509804,excluded,NR,"I have a male patient with bladder urothelial carcinoma (BLCA) who has a tumor mutational burden (TMB) of 8.0, and his mRNA TPM expression from a bladder biopsy was assessed to characterize the tumor immune microenvironment. Given these findings, should I expect a favorable response to treatment with Atezolizumab?","I have a male patient with bladder urothelial carcinoma (BLCA) who has a tumor mutational burden (TMB) of 8.0, and his mRNA TPM expression from a bladder biopsy was assessed to characterize the tumor immune microenvironment. Given these findings, should I expect a favorable response to treatment with Atezolizumab?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/0a7c20-ar-0a7c209.pkl. "
BLCA,,,,NR,"I have a female patient with bladder urothelial carcinoma whose lymph node biopsy was analyzed for mRNA TPM expression to assess the tumor immune microenvironment, although the tumor mutational burden is not available. Based on these factors, what is the likelihood that she will respond to Atezolizumab therapy?","I have a female patient with bladder urothelial carcinoma whose lymph node biopsy was analyzed for mRNA TPM expression to assess the tumor immune microenvironment, although the tumor mutational burden is not available. Based on these factors, what is the likelihood that she will respond to Atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/0bdb34-ar-0bdb342.pkl. "
BLCA,9.0,,excluded,NR,"I have a male patient with bladder urothelial carcinoma who underwent a ureter biopsy that assessed mRNA TPM expression of the tumor immune microenvironment, and his tumor mutational burden is 9.0. Based on this molecular profile, how likely is he to respond to treatment with Atezolizumab?","I have a male patient with bladder urothelial carcinoma who underwent a ureter biopsy that assessed mRNA TPM expression of the tumor immune microenvironment, and his tumor mutational burden is 9.0. Based on this molecular profile, how likely is he to respond to treatment with Atezolizumab?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/0ce9c9-ar-0ce9c98.pkl. "
BLCA,4.0,0.137254902,desert,NR,"In a female patient with bladder urothelial carcinoma, mRNA TPM expression was obtained from a bladder biopsy to evaluate the tumor immune microenvironment, and the tumor mutational burden is 4.0. Considering treatment with atezolizumab, how likely is it that she will respond to this therapy?","In a female patient with bladder urothelial carcinoma, mRNA TPM expression was obtained from a bladder biopsy to evaluate the tumor immune microenvironment, and the tumor mutational burden is 4.0. Considering treatment with atezolizumab, how likely is it that she will respond to this therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/0d855c-ar-0d855cf.pkl. "
BLCA,32.0,4.098039216,excluded,NR,"In a patient with bladder urothelial carcinoma, mRNA TPM expression was measured via a ureter biopsy to evaluate the tumor immune microenvironment, and the tumor mutational burden is 32.0. Based on these data, what is the likelihood that the patient will respond to Atezolizumab therapy?","In a patient with bladder urothelial carcinoma, mRNA TPM expression was measured via a ureter biopsy to evaluate the tumor immune microenvironment, and the tumor mutational burden is 32.0. Based on these data, what is the likelihood that the patient will respond to Atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/0f956e-ar-0f956e7.pkl. "
BLCA,21.0,3.529411765,desert,NR,"In a patient with bladder urothelial carcinoma who has undergone a biopsy with mRNA TPM expression profiling of the tumor immune microenvironment and exhibits a tumor mutational burden of 21.0, how likely is the patient to respond to Atezolizumab therapy?","In a patient with bladder urothelial carcinoma who has undergone a biopsy with mRNA TPM expression profiling of the tumor immune microenvironment and exhibits a tumor mutational burden of 21.0, how likely is the patient to respond to Atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/110501-ar-110501d.pkl. "
BLCA,10.0,1.078431373,inflamed,NR,"I have a male patient with bladder urothelial carcinoma whose mRNA TPM expression was evaluated from a kidney biopsy to assess the tumor immune microenvironment. With a tumor mutational burden of 10.0, would this patient likely respond to Atezolizumab therapy?","I have a male patient with bladder urothelial carcinoma whose mRNA TPM expression was evaluated from a kidney biopsy to assess the tumor immune microenvironment. With a tumor mutational burden of 10.0, would this patient likely respond to Atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/12502d-ar-12502d9.pkl. "
BLCA,38.0,6.68627451,desert,R,"In a male patient with bladder urothelial carcinoma (BLCA) who has undergone a bladder biopsy with mRNA TPM expression profiling to assess the tumor immune microenvironment, and with a tumor mutational burden (TMB) of 38.0, how likely is it that treatment with Atezolizumab will be effective?","In a male patient with bladder urothelial carcinoma (BLCA) who has undergone a bladder biopsy with mRNA TPM expression profiling to assess the tumor immune microenvironment, and with a tumor mutational burden (TMB) of 38.0, how likely is it that treatment with Atezolizumab will be effective?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/149386-ar-1493861.pkl. "
BLCA,7.0,0.568627451,excluded,R,"In a female patient with bladder urothelial carcinoma, where bladder biopsy mRNA TPM expression was used to assess the tumor immune microenvironment and the tumor mutational burden is 7.0, is treatment with Atezolizumab likely to be effective?","In a female patient with bladder urothelial carcinoma, where bladder biopsy mRNA TPM expression was used to assess the tumor immune microenvironment and the tumor mutational burden is 7.0, is treatment with Atezolizumab likely to be effective?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/14df63-ar-14df63a.pkl. "
BLCA,5.0,0.274509804,excluded,NR,"In a male patient with bladder urothelial carcinoma who has a tumor mutational burden of 5.0 and available mRNA TPM expression data from a bladder biopsy assessing the tumor immune microenvironment, how likely is a response to atezolizumab therapy?","In a male patient with bladder urothelial carcinoma who has a tumor mutational burden of 5.0 and available mRNA TPM expression data from a bladder biopsy assessing the tumor immune microenvironment, how likely is a response to atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/166a41-ar-166a419.pkl. "
BLCA,15.0,,desert,NR,"I have a male patient with bladder urothelial carcinoma whose tumor immune microenvironment was assessed using mRNA TPM expression from a bladder biopsy, and his tumor mutational burden is 15.0. Based on these factors, is he likely to respond favorably to Atezolizumab therapy?","I have a male patient with bladder urothelial carcinoma whose tumor immune microenvironment was assessed using mRNA TPM expression from a bladder biopsy, and his tumor mutational burden is 15.0. Based on these factors, is he likely to respond favorably to Atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/180398-ar-1803982.pkl. "
BLCA,,0.215686275,excluded,NR,"I have a male patient with bladder urothelial carcinoma whose mRNA TPM expression was measured from a kidney biopsy to assess the tumor immune microenvironment, although the tumor mutational burden is not available. Considering these factors, can we expect this patient to respond to atezolizumab therapy?","I have a male patient with bladder urothelial carcinoma whose mRNA TPM expression was measured from a kidney biopsy to assess the tumor immune microenvironment, although the tumor mutational burden is not available. Considering these factors, can we expect this patient to respond to atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/181b63-ar-181b638.pkl. "
BLCA,,,,NR,"A male patient with bladder urothelial carcinoma underwent a lung biopsy for mRNA TPM expression profiling of the tumor immune microenvironment, and his tumor mutational burden is unavailable. Given these factors, would treatment with atezolizumab likely be effective?","A male patient with bladder urothelial carcinoma underwent a lung biopsy for mRNA TPM expression profiling of the tumor immune microenvironment, and his tumor mutational burden is unavailable. Given these factors, would treatment with atezolizumab likely be effective?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/187e05-ar-187e056.pkl. "
BLCA,18.0,2.039215686,excluded,NR,"In a male patient with bladder urothelial carcinoma, whose bladder biopsy shows mRNA TPM expression indicative of the tumor immune microenvironment and a tumor mutational burden of 18.0, would treatment with Atezolizumab likely result in a favorable therapeutic response?","In a male patient with bladder urothelial carcinoma, whose bladder biopsy shows mRNA TPM expression indicative of the tumor immune microenvironment and a tumor mutational burden of 18.0, would treatment with Atezolizumab likely result in a favorable therapeutic response?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/18a4da-ar-18a4dab.pkl. "
BLCA,7.0,0.392156863,inflamed,NR,"We have a male patient with bladder urothelial carcinoma whose tumor microenvironment was evaluated via mRNA TPM expression from a ureter biopsy. The tumor mutational burden is 7.0. Given these findings, what is the likelihood that the patient will respond to treatment with atezolizumab?","We have a male patient with bladder urothelial carcinoma whose tumor microenvironment was evaluated via mRNA TPM expression from a ureter biopsy. The tumor mutational burden is 7.0. Given these findings, what is the likelihood that the patient will respond to treatment with atezolizumab?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/18b935-ar-18b9351.pkl. "
BLCA,19.0,1.803921569,,NR,"I have a male patient with bladder urothelial carcinoma whose mRNA expression profile (assessed via TPM from a bladder biopsy) was evaluated to study the tumor immune microenvironment. With a tumor mutational burden of 19.0, do you think he is likely to respond favorably to Atezolizumab therapy?","I have a male patient with bladder urothelial carcinoma whose mRNA expression profile (assessed via TPM from a bladder biopsy) was evaluated to study the tumor immune microenvironment. With a tumor mutational burden of 19.0, do you think he is likely to respond favorably to Atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/18bc10-ar-18bc107.pkl. "
BLCA,5.0,0.470588235,excluded,NR,"For a male patient with bladder urothelial carcinoma, with a tumor mutational burden of 5.0 and mRNA TPM expression data obtained from a bladder biopsy evaluating the tumor immune microenvironment, how likely is it that he will respond to Atezolizumab therapy?","For a male patient with bladder urothelial carcinoma, with a tumor mutational burden of 5.0 and mRNA TPM expression data obtained from a bladder biopsy evaluating the tumor immune microenvironment, how likely is it that he will respond to Atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/18be5b-ar-18be5b3.pkl. "
BLCA,5.0,0.431372549,excluded,NR,"For a patient with bladder urothelial carcinoma who has undergone a bladder biopsy with mRNA TPM expression profiling to assess the tumor immune microenvironment and has a tumor mutational burden of 5.0, would treatment with Atezolizumab be expected to yield a favorable response?","For a patient with bladder urothelial carcinoma who has undergone a bladder biopsy with mRNA TPM expression profiling to assess the tumor immune microenvironment and has a tumor mutational burden of 5.0, would treatment with Atezolizumab be expected to yield a favorable response?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/19fec8-ar-19fec8f.pkl. "
BLCA,8.0,1.176470588,excluded,NR,"For a male patient with bladder urothelial carcinoma who has a tumor mutational burden of 8.0 and mRNA TPM expression data from a bladder biopsy assessing the immune microenvironment, how likely is it that he would respond to atezolizumab therapy?","For a male patient with bladder urothelial carcinoma who has a tumor mutational burden of 8.0 and mRNA TPM expression data from a bladder biopsy assessing the immune microenvironment, how likely is it that he would respond to atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/1a87df-ar-1a87df7.pkl. "
BLCA,13.0,0.294117647,desert,NR,"I have a female patient with bladder urothelial carcinoma. An mRNA TPM analysis from a ureter biopsy was performed to evaluate her tumor immune microenvironment, and her tumor mutational burden is 13.0. Based on these findings, what is her likelihood of responding favorably to Atezolizumab therapy?","I have a female patient with bladder urothelial carcinoma. An mRNA TPM analysis from a ureter biopsy was performed to evaluate her tumor immune microenvironment, and her tumor mutational burden is 13.0. Based on these findings, what is her likelihood of responding favorably to Atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/1ab1b2-ar-1ab1b28.pkl. "
BLCA,16.0,1.862745098,excluded,R,"We have a male patient with bladder urothelial carcinoma whose tumoral mRNA TPM expression has been measured from a kidney biopsy to assess the immune microenvironment. His tumor mutational burden is 16.0. Given these factors, how likely is he to respond to Atezolizumab therapy?","We have a male patient with bladder urothelial carcinoma whose tumoral mRNA TPM expression has been measured from a kidney biopsy to assess the immune microenvironment. His tumor mutational burden is 16.0. Given these factors, how likely is he to respond to Atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/1abf01-ar-1abf01d.pkl. "
BLCA,2.0,0.647058824,excluded,NR,"In a male patient with bladder urothelial carcinoma, where mRNA TPM expression was measured from a kidney biopsy to assess the tumor immune microenvironment and the tumor mutational burden is 2.0, what is the likelihood of response to atezolizumab therapy?","In a male patient with bladder urothelial carcinoma, where mRNA TPM expression was measured from a kidney biopsy to assess the tumor immune microenvironment and the tumor mutational burden is 2.0, what is the likelihood of response to atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/1ac4e3-ar-1ac4e3d.pkl. "
BLCA,,,excluded,NR,"I have a female patient with bladder urothelial carcinoma who underwent a bladder biopsy with mRNA TPM expression analysis to evaluate the tumor immune microenvironment. With a tumor mutational burden that is not available, how likely is it that she would respond to therapy with atezolizumab?","I have a female patient with bladder urothelial carcinoma who underwent a bladder biopsy with mRNA TPM expression analysis to evaluate the tumor immune microenvironment. With a tumor mutational burden that is not available, how likely is it that she would respond to therapy with atezolizumab?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/1c0ecf-ar-1c0ecfb.pkl. "
BLCA,7.0,0.549019608,excluded,NR,"In a male patient with bladder urothelial carcinoma, mRNA expression profiling from a bladder biopsy was conducted to assess the tumor immune microenvironment, and the tumor mutational burden is reported as 7.0 mutations per megabase. Based on these findings, how likely is the patient to respond to Atezolizumab therapy?","In a male patient with bladder urothelial carcinoma, mRNA expression profiling from a bladder biopsy was conducted to assess the tumor immune microenvironment, and the tumor mutational burden is reported as 7.0 mutations per megabase. Based on these findings, how likely is the patient to respond to Atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/1c8b08-ar-1c8b086.pkl. "
BLCA,20.0,4.019607843,desert,NR,"We have a male patient with bladder urothelial carcinoma who underwent a bladder biopsy with mRNA TPM expression profiling to assess the tumor immune microenvironment. His tumor mutational burden is 20.0. Given these factors, how likely is it that he will respond to Atezolizumab therapy?","We have a male patient with bladder urothelial carcinoma who underwent a bladder biopsy with mRNA TPM expression profiling to assess the tumor immune microenvironment. His tumor mutational burden is 20.0. Given these factors, how likely is it that he will respond to Atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/1dda30-ar-1dda30f.pkl. "
BLCA,5.0,1.431372549,inflamed,NR,"In a female patient with bladder urothelial carcinoma (BLCA) who has a tumor mutational burden (TMB) of 5.0 and mRNA TPM expression data from a bladder biopsy assessing the tumor immune microenvironment, how likely is she to respond to Atezolizumab therapy?","In a female patient with bladder urothelial carcinoma (BLCA) who has a tumor mutational burden (TMB) of 5.0 and mRNA TPM expression data from a bladder biopsy assessing the tumor immune microenvironment, how likely is she to respond to Atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/1e9c4d-ar-1e9c4d1.pkl. "
BLCA,38.0,4.509803922,inflamed,R,"For a male patient with bladder urothelial carcinoma, whose bladder biopsy shows mRNA TPM expression levels and a tumor mutational burden of 38.0, is he likely to have a favorable response to atezolizumab therapy?","For a male patient with bladder urothelial carcinoma, whose bladder biopsy shows mRNA TPM expression levels and a tumor mutational burden of 38.0, is he likely to have a favorable response to atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/1f66db-ar-1f66db5.pkl. "
BLCA,6.0,0.549019608,desert,NR,"In a patient with bladder urothelial carcinoma who underwent a kidney biopsy for mRNA TPM expression analysis of the tumor immune microenvironment, the tumor mutational burden is 6.0. Given these findings, how likely is the patient to respond to atezolizumab therapy?","In a patient with bladder urothelial carcinoma who underwent a kidney biopsy for mRNA TPM expression analysis of the tumor immune microenvironment, the tumor mutational burden is 6.0. Given these findings, how likely is the patient to respond to atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/1f83eb-ar-1f83ebd.pkl. "
BLCA,8.0,1.235294118,inflamed,NR,"In a male patient with bladder urothelial carcinoma, mRNA TPM expression from a bladder biopsy was measured to evaluate the tumor immune microenvironment, and his tumor mutational burden is 8.0 mutations per megabase. Given these findings, how likely is he to benefit from treatment with atezolizumab?","In a male patient with bladder urothelial carcinoma, mRNA TPM expression from a bladder biopsy was measured to evaluate the tumor immune microenvironment, and his tumor mutational burden is 8.0 mutations per megabase. Given these findings, how likely is he to benefit from treatment with atezolizumab?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/1fa6bc-ar-1fa6bcb.pkl. "
BLCA,13.0,2.392156863,inflamed,R,"Given a male patient with bladder urothelial carcinoma who has undergone mRNA TPM expression profiling from a bladder biopsy, and whose tumor mutational burden is 13.0, what is the likelihood that he will respond to Atezolizumab therapy?","Given a male patient with bladder urothelial carcinoma who has undergone mRNA TPM expression profiling from a bladder biopsy, and whose tumor mutational burden is 13.0, what is the likelihood that he will respond to Atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/203dcf-ar-203dcf1.pkl. "
BLCA,5.0,0.294117647,excluded,NR,"I have a patient with bladder urothelial carcinoma whose tumor immune microenvironment was characterized using mRNA TPM expression from a kidney biopsy, and the tumor's mutational burden is 5.0. In light of these findings, would treatment with Atezolizumab be expected to be effective for this patient?","I have a patient with bladder urothelial carcinoma whose tumor immune microenvironment was characterized using mRNA TPM expression from a kidney biopsy, and the tumor's mutational burden is 5.0. In light of these findings, would treatment with Atezolizumab be expected to be effective for this patient?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/2070b4-ar-2070b41.pkl. "
BLCA,5.0,0.235294118,desert,NR,"In a female patient with bladder urothelial carcinoma, whose bladder biopsy revealed mRNA TPM expression profiling of the tumor immune microenvironment and a tumor mutational burden of 5.0, what is the expected likelihood of response to atezolizumab therapy?","In a female patient with bladder urothelial carcinoma, whose bladder biopsy revealed mRNA TPM expression profiling of the tumor immune microenvironment and a tumor mutational burden of 5.0, what is the expected likelihood of response to atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/230959-ar-2309593.pkl. "
BLCA,5.0,0.333333333,excluded,NR,"In a patient with bladder urothelial carcinoma whose tumor immune microenvironment was evaluated via mRNA TPM expression from a kidney biopsy and who has a TMB of 5.0, do available data support a likely clinical response to atezolizumab therapy?","In a patient with bladder urothelial carcinoma whose tumor immune microenvironment was evaluated via mRNA TPM expression from a kidney biopsy and who has a TMB of 5.0, do available data support a likely clinical response to atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/23aa15-ar-23aa15d.pkl. "
BLCA,,1.823529412,desert,R,"In a male patient with bladder urothelial carcinoma, mRNA TPM expression from a separate biopsy was used to assess the tumor immune microenvironment, but the tumor mutational burden is not available. Given these factors, what is the likelihood that the patient would respond to treatment with atezolizumab?","In a male patient with bladder urothelial carcinoma, mRNA TPM expression from a separate biopsy was used to assess the tumor immune microenvironment, but the tumor mutational burden is not available. Given these factors, what is the likelihood that the patient would respond to treatment with atezolizumab?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/25510f-ar-25510f3.pkl. "
BLCA,12.0,1.529411765,inflamed,R,"We have a female patient with bladder urothelial carcinoma whose mRNA TPM expression was evaluated from a lymph node biopsy to characterize the tumor immune microenvironment, and her tumor mutational burden (TMB) is 12.0. Given these findings, how predictive is a positive response to atezolizumab therapy?","We have a female patient with bladder urothelial carcinoma whose mRNA TPM expression was evaluated from a lymph node biopsy to characterize the tumor immune microenvironment, and her tumor mutational burden (TMB) is 12.0. Given these findings, how predictive is a positive response to atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/2570ff-ar-2570ff4.pkl. "
BLCA,1.0,0.274509804,excluded,NR,"In a patient with bladder urothelial carcinoma, a bladder biopsy showed mRNA TPM expression indicating the tumor immune microenvironment and a tumor mutational burden of 1.0. Would these findings support the use of Atezolizumab, and are they predictive of a favorable response to therapy?","In a patient with bladder urothelial carcinoma, a bladder biopsy showed mRNA TPM expression indicating the tumor immune microenvironment and a tumor mutational burden of 1.0. Would these findings support the use of Atezolizumab, and are they predictive of a favorable response to therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/26104d-ar-26104d5.pkl. "
BLCA,6.0,0.431372549,excluded,NR,"I have a patient with bladder urothelial carcinoma (BLCA) whose tumor immune microenvironment was characterized by mRNA TPM expression analysis from a bladder biopsy, and the tumor mutational burden (TMB) is 6.0. Given these findings, would this patient be expected to respond to treatment with atezolizumab?","I have a patient with bladder urothelial carcinoma (BLCA) whose tumor immune microenvironment was characterized by mRNA TPM expression analysis from a bladder biopsy, and the tumor mutational burden (TMB) is 6.0. Given these findings, would this patient be expected to respond to treatment with atezolizumab?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/262422-ar-2624229.pkl. "
BLCA,8.0,0.745098039,excluded,R,"A female patient with bladder urothelial carcinoma has undergone a bladder biopsy, yielding mRNA TPM expression data for the tumor immune microenvironment, and her tumor mutational burden is 8.0. Based on these factors, how likely is she to respond to Atezolizumab therapy?","A female patient with bladder urothelial carcinoma has undergone a bladder biopsy, yielding mRNA TPM expression data for the tumor immune microenvironment, and her tumor mutational burden is 8.0. Based on these factors, how likely is she to respond to Atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/27299a-ar-27299ae.pkl. "
BLCA,6.0,0.568627451,inflamed,NR,"I have a male patient with bladder urothelial carcinoma. The tumor's immune microenvironment was evaluated using mRNA TPM expression from a kidney biopsy, and the tumor mutational burden is 6.0. Based on these parameters, could we expect a favorable response to Atezolizumab?","I have a male patient with bladder urothelial carcinoma. The tumor's immune microenvironment was evaluated using mRNA TPM expression from a kidney biopsy, and the tumor mutational burden is 6.0. Based on these parameters, could we expect a favorable response to Atezolizumab?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/286870-ar-2868703.pkl. "
BLCA,22.0,,desert,NR,"I have a male patient with bladder urothelial carcinoma. A bladder biopsy revealed mRNA TPM expression to assess the tumor immune microenvironment, and the tumor mutational burden is 22.0. Given these findings, how likely is it that the patient will respond to Atezolizumab therapy?","I have a male patient with bladder urothelial carcinoma. A bladder biopsy revealed mRNA TPM expression to assess the tumor immune microenvironment, and the tumor mutational burden is 22.0. Given these findings, how likely is it that the patient will respond to Atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/28e603-ar-28e6031.pkl. "
BLCA,1.0,,excluded,NR,"In a male patient with bladder urothelial carcinoma (BLCA) whose bladder biopsy shows an mRNA TPM profile corresponding to a tumor mutational burden (TMB) of 1.0, how likely is it that treatment with atezolizumab will be effective?","In a male patient with bladder urothelial carcinoma (BLCA) whose bladder biopsy shows an mRNA TPM profile corresponding to a tumor mutational burden (TMB) of 1.0, how likely is it that treatment with atezolizumab will be effective?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/297c03-ar-297c030.pkl. "
BLCA,,0.490196078,desert,NR,"I am evaluating a female patient with bladder urothelial carcinoma whose tumor immune microenvironment was characterized using mRNA TPM expression from a ureter biopsy. However, tumor mutational burden data are not available. Given this context, what is the likelihood that she will respond to atezolizumab therapy?","I am evaluating a female patient with bladder urothelial carcinoma whose tumor immune microenvironment was characterized using mRNA TPM expression from a ureter biopsy. However, tumor mutational burden data are not available. Given this context, what is the likelihood that she will respond to atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/29da92-ar-29da928.pkl. "
BLCA,2.0,0.156862745,desert,NR,"In a male patient with bladder urothelial carcinoma whose tumor immune microenvironment was assessed via mRNA TPM expression from a kidney biopsy, and who has a tumor mutational burden of 2.0, how likely is a response to Atezolizumab therapy?","In a male patient with bladder urothelial carcinoma whose tumor immune microenvironment was assessed via mRNA TPM expression from a kidney biopsy, and who has a tumor mutational burden of 2.0, how likely is a response to Atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/2b672f-ar-2b672f4.pkl. "
BLCA,11.0,1.294117647,excluded,NR,"For a male patient with bladder urothelial carcinoma whose bladder biopsy revealed mRNA TPM expression profiles for immune microenvironment analysis and a tumor mutational burden of 11.0, how likely is it that he will respond to Atezolizumab therapy?","For a male patient with bladder urothelial carcinoma whose bladder biopsy revealed mRNA TPM expression profiles for immune microenvironment analysis and a tumor mutational burden of 11.0, how likely is it that he will respond to Atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/2bba8c-ar-2bba8cb.pkl. "
BLCA,9.0,0.431372549,desert,NR,"I have a male patient with bladder urothelial carcinoma whose tumor mutational burden is 9.0, and mRNA TPM expression from a bladder biopsy has been measured to assess the tumor immune microenvironment. Based on this information, is he likely to benefit from Atezolizumab therapy?","I have a male patient with bladder urothelial carcinoma whose tumor mutational burden is 9.0, and mRNA TPM expression from a bladder biopsy has been measured to assess the tumor immune microenvironment. Based on this information, is he likely to benefit from Atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/2c9586-ar-2c95861.pkl. "
BLCA,,,inflamed,NR,"I have a male patient with bladder urothelial carcinoma (BLCA), and his mRNA TPM expression was assessed via a kidney biopsy to evaluate the tumor immune microenvironment. The tumor mutational burden (TMB) is not reported. Given these parameters, how predictive is a response to Atezolizumab therapy in this context?","I have a male patient with bladder urothelial carcinoma (BLCA), and his mRNA TPM expression was assessed via a kidney biopsy to evaluate the tumor immune microenvironment. The tumor mutational burden (TMB) is not reported. Given these parameters, how predictive is a response to Atezolizumab therapy in this context?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/2dc3f0-ar-2dc3f04.pkl. "
BLCA,14.0,2.705882353,excluded,NR,I have a male patient with bladder urothelial carcinoma (BLCA) who underwent a kidney biopsy to assess mRNA TPM expression for evaluating the tumor immune microenvironment. The tumor mutational burden (TMB) is 14.0. Could you provide insight into whether this patient is likely to respond to Atezolizumab therapy?,I have a male patient with bladder urothelial carcinoma (BLCA) who underwent a kidney biopsy to assess mRNA TPM expression for evaluating the tumor immune microenvironment. The tumor mutational burden (TMB) is 14.0. Could you provide insight into whether this patient is likely to respond to Atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/2e7aa8-ar-2e7aa8f.pkl. 
BLCA,18.0,1.764705882,,R,"I have a male patient with bladder urothelial carcinoma (BLCA) whose tumor biopsy revealed mRNA TPM expression data and a tumor mutational burden (TMB) of 18.0. Considering these molecular findings, how likely is he to respond to atezolizumab therapy?","I have a male patient with bladder urothelial carcinoma (BLCA) whose tumor biopsy revealed mRNA TPM expression data and a tumor mutational burden (TMB) of 18.0. Considering these molecular findings, how likely is he to respond to atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/2e9ac0-ar-2e9ac0b.pkl. "
BLCA,13.0,1.137254902,inflamed,R,"For a male patient with bladder urothelial carcinoma and a tumor mutational burden of 13.0, with mRNA TPM expression data from a bladder biopsy characterizing the tumor immune microenvironment, how likely is it that he will respond to Atezolizumab therapy?","For a male patient with bladder urothelial carcinoma and a tumor mutational burden of 13.0, with mRNA TPM expression data from a bladder biopsy characterizing the tumor immune microenvironment, how likely is it that he will respond to Atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/2eb07d-ar-2eb07de.pkl. "
BLCA,8.0,0.450980392,excluded,NR,"In a female patient with bladder urothelial carcinoma evaluated by mRNA TPM expression from a biopsy to characterize the tumor immune microenvironment and a measured tumor mutational burden of 8.0, what is the likelihood of a positive response to Atezolizumab therapy?","In a female patient with bladder urothelial carcinoma evaluated by mRNA TPM expression from a biopsy to characterize the tumor immune microenvironment and a measured tumor mutational burden of 8.0, what is the likelihood of a positive response to Atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/2f2289-ar-2f22893.pkl. "
BLCA,6.0,,excluded,R,"In a female patient with bladder urothelial carcinoma, mRNA TPM expression profiling from a bladder biopsy has been performed to assess the tumor immune microenvironment, and the tumor mutational burden is 6.0. Given these findings, is atezolizumab likely to be an effective treatment option?","In a female patient with bladder urothelial carcinoma, mRNA TPM expression profiling from a bladder biopsy has been performed to assess the tumor immune microenvironment, and the tumor mutational burden is 6.0. Given these findings, is atezolizumab likely to be an effective treatment option?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/30b5c6-ar-30b5c6c.pkl. "
BLCA,,,excluded,NR,"In a male patient with bladder urothelial carcinoma who underwent mRNA TPM expression profiling from a bladder biopsy to evaluate the tumor immune microenvironment, and with a tumor mutational burden reported as 'nan', would treatment with atezolizumab be expected to yield a favorable response?","In a male patient with bladder urothelial carcinoma who underwent mRNA TPM expression profiling from a bladder biopsy to evaluate the tumor immune microenvironment, and with a tumor mutational burden reported as 'nan', would treatment with atezolizumab be expected to yield a favorable response?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/30cf07-ar-30cf07d.pkl. "
BLCA,23.0,4.235294118,inflamed,R,"For a male patient with bladder urothelial carcinoma who has undergone a bladder biopsy with mRNA TPM expression profiling and exhibits a tumor mutational burden of 23.0, how predictive are these findings of a favorable response to Atezolizumab therapy?","For a male patient with bladder urothelial carcinoma who has undergone a bladder biopsy with mRNA TPM expression profiling and exhibits a tumor mutational burden of 23.0, how predictive are these findings of a favorable response to Atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/31d917-ar-31d9176.pkl. "
BLCA,,0.705882353,,NR,"I am managing a female patient with bladder urothelial carcinoma (BLCA) whose mRNA TPM expression was evaluated from a lymph node biopsy to assess the tumor immune microenvironment. The tumor mutational burden (TMB) is unavailable. Given these factors, how likely is the patient to respond to atezolizumab therapy?","I am managing a female patient with bladder urothelial carcinoma (BLCA) whose mRNA TPM expression was evaluated from a lymph node biopsy to assess the tumor immune microenvironment. The tumor mutational burden (TMB) is unavailable. Given these factors, how likely is the patient to respond to atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/31f41d-ar-31f41dd.pkl. "
BLCA,2.0,,,NR,"For a male patient with bladder urothelial carcinoma, whose tumor mutational burden is 2.0 and mRNA TPM expression profiling from a lymph node biopsy has been conducted to assess the tumor immune microenvironment, how likely is it that the patient would respond to Atezolizumab therapy?","For a male patient with bladder urothelial carcinoma, whose tumor mutational burden is 2.0 and mRNA TPM expression profiling from a lymph node biopsy has been conducted to assess the tumor immune microenvironment, how likely is it that the patient would respond to Atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/3330c0-ar-3330c03.pkl. "
BLCA,,,,NR,"In a male patient with bladder urothelial carcinoma whose tumor immune microenvironment was characterized via mRNA TPM expression analysis from a bladder biopsy, and with an unreported (nan) tumor mutational burden, how likely is a positive response to treatment with atezolizumab?","In a male patient with bladder urothelial carcinoma whose tumor immune microenvironment was characterized via mRNA TPM expression analysis from a bladder biopsy, and with an unreported (nan) tumor mutational burden, how likely is a positive response to treatment with atezolizumab?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/34430e-ar-34430ef.pkl. "
BLCA,7.0,0.333333333,excluded,NR,"In a patient with bladder urothelial carcinoma who has a tumor mutational burden of 7.0 and mRNA TPM expression data from a bladder biopsy assessing the tumor immune microenvironment, how likely is it that the patient will respond to Atezolizumab therapy?","In a patient with bladder urothelial carcinoma who has a tumor mutational burden of 7.0 and mRNA TPM expression data from a bladder biopsy assessing the tumor immune microenvironment, how likely is it that the patient will respond to Atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/36851b-ar-36851bc.pkl. "
BLCA,1.0,0.607843137,inflamed,NR,"Given that my patient has bladder urothelial carcinoma (BLCA) with a tumor mutational burden (TMB) of 1.0 and mRNA TPM expression from a bladder biopsy assessing the tumor immune microenvironment, how likely is the patient to benefit from Atezolizumab treatment?","Given that my patient has bladder urothelial carcinoma (BLCA) with a tumor mutational burden (TMB) of 1.0 and mRNA TPM expression from a bladder biopsy assessing the tumor immune microenvironment, how likely is the patient to benefit from Atezolizumab treatment?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/36a922-ar-36a9225.pkl. "
BLCA,7.0,0.352941176,excluded,NR,"For a male patient with bladder urothelial carcinoma evaluated via a ureter biopsy that assessed mRNA TPM expression and a tumor mutational burden of 7.0, is Atezolizumab likely to be an effective treatment option?","For a male patient with bladder urothelial carcinoma evaluated via a ureter biopsy that assessed mRNA TPM expression and a tumor mutational burden of 7.0, is Atezolizumab likely to be an effective treatment option?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/36d873-ar-36d8739.pkl. "
BLCA,5.0,,excluded,NR,"We have a male patient diagnosed with bladder urothelial carcinoma, and his tumor mutational burden (TMB) is 5.0. RNA TPM expression analysis from a bladder biopsy was performed to evaluate the tumor immune microenvironment. Given these findings, how likely is it that he will respond to treatment with atezolizumab?","We have a male patient diagnosed with bladder urothelial carcinoma, and his tumor mutational burden (TMB) is 5.0. RNA TPM expression analysis from a bladder biopsy was performed to evaluate the tumor immune microenvironment. Given these findings, how likely is it that he will respond to treatment with atezolizumab?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/3894ac-ar-3894ac3.pkl. "
BLCA,6.0,,excluded,NR,"For a male patient with bladder urothelial carcinoma who has an mRNA TPM expression profile from a bladder biopsy evaluating the tumor immune microenvironment and a tumor mutational burden of 6.0, how likely is it that the patient would respond to Atezolizumab therapy?","For a male patient with bladder urothelial carcinoma who has an mRNA TPM expression profile from a bladder biopsy evaluating the tumor immune microenvironment and a tumor mutational burden of 6.0, how likely is it that the patient would respond to Atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/39eb94-ar-39eb94f.pkl. "
BLCA,,,,NR,"A male patient with bladder urothelial carcinoma has had mRNA TPM expression measured from a lung biopsy to assess the tumor immune microenvironment, and his tumor mutational burden data is unavailable. Given these findings, what is the likelihood that he will respond to atezolizumab therapy?","A male patient with bladder urothelial carcinoma has had mRNA TPM expression measured from a lung biopsy to assess the tumor immune microenvironment, and his tumor mutational burden data is unavailable. Given these findings, what is the likelihood that he will respond to atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/3a1c96-ar-3a1c963.pkl. "
BLCA,2.0,0.176470588,excluded,NR,"I have a male patient with bladder urothelial carcinoma who underwent a lymph node biopsy for mRNA TPM expression analysis to assess the tumor immune microenvironment, and his tumor mutational burden is 2.0. Based on these parameters, is he likely to respond to Atezolizumab therapy?","I have a male patient with bladder urothelial carcinoma who underwent a lymph node biopsy for mRNA TPM expression analysis to assess the tumor immune microenvironment, and his tumor mutational burden is 2.0. Based on these parameters, is he likely to respond to Atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/3b1066-ar-3b1066e.pkl. "
BLCA,44.0,5.823529412,inflamed,R,"For a male patient with bladder urothelial carcinoma, mRNA TPM expression profiling from a bladder biopsy has been performed to assess the tumor immune microenvironment, and the tumor mutational burden is 44.0. Given these findings, would you consider the patient a suitable candidate for atezolizumab therapy?","For a male patient with bladder urothelial carcinoma, mRNA TPM expression profiling from a bladder biopsy has been performed to assess the tumor immune microenvironment, and the tumor mutational burden is 44.0. Given these findings, would you consider the patient a suitable candidate for atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/3b15b4-ar-3b15b4c.pkl. "
BLCA,15.0,2.235294118,excluded,NR,"I have a male patient with bladder urothelial carcinoma whose tumor immune microenvironment was evaluated using mRNA TPM expression from a kidney biopsy. The patient has a tumor mutational burden of 15.0 mutations per megabase. Based on these findings, is a favorable response to atezolizumab likely?","I have a male patient with bladder urothelial carcinoma whose tumor immune microenvironment was evaluated using mRNA TPM expression from a kidney biopsy. The patient has a tumor mutational burden of 15.0 mutations per megabase. Based on these findings, is a favorable response to atezolizumab likely?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/3cb94b-ar-3cb94b0.pkl. "
BLCA,17.0,1.411764706,excluded,R,"For a male patient with bladder urothelial carcinoma (BLCA), whose mRNA TPM expression from a lymph node biopsy has been analyzed to assess the tumor immune microenvironment and who exhibits a tumor mutational burden of 17.0, would treatment with Atezolizumab likely yield a favorable therapeutic response?","For a male patient with bladder urothelial carcinoma (BLCA), whose mRNA TPM expression from a lymph node biopsy has been analyzed to assess the tumor immune microenvironment and who exhibits a tumor mutational burden of 17.0, would treatment with Atezolizumab likely yield a favorable therapeutic response?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/3e04eb-ar-3e04eb9.pkl. "
BLCA,11.0,1.215686275,desert,NR,"We have a male patient with bladder urothelial carcinoma whose mRNA TPM expression was evaluated from a kidney biopsy to assess the tumor immune microenvironment. With a tumor mutational burden of 11.0, would you anticipate a favorable response to Atezolizumab therapy?","We have a male patient with bladder urothelial carcinoma whose mRNA TPM expression was evaluated from a kidney biopsy to assess the tumor immune microenvironment. With a tumor mutational burden of 11.0, would you anticipate a favorable response to Atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/3e8baf-ar-3e8baff.pkl. "
BLCA,,,desert,NR,"We have a male patient diagnosed with bladder urothelial carcinoma. A bladder biopsy was performed, and the mRNA TPM expression was evaluated to assess the tumor immune microenvironment. However, the tumor mutational burden (TMB) value is not available. Given these findings, how likely is the patient to respond to atezolizumab therapy?","We have a male patient diagnosed with bladder urothelial carcinoma. A bladder biopsy was performed, and the mRNA TPM expression was evaluated to assess the tumor immune microenvironment. However, the tumor mutational burden (TMB) value is not available. Given these findings, how likely is the patient to respond to atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/3ee5dc-ar-3ee5dcd.pkl. "
BLCA,,0.431372549,excluded,NR,"For a male patient with bladder urothelial carcinoma, mRNA TPM expression analysis from a bladder biopsy was conducted to assess the tumor immune microenvironment, but the tumor mutational burden (TMB) value is reported as ""nan."" Given these findings, what is the likelihood that the patient will respond to Atezolizumab therapy?","For a male patient with bladder urothelial carcinoma, mRNA TPM expression analysis from a bladder biopsy was conducted to assess the tumor immune microenvironment, but the tumor mutational burden (TMB) value is reported as ""nan."" Given these findings, what is the likelihood that the patient will respond to Atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/415f36-ar-415f36a.pkl. "
BLCA,12.0,0.392156863,desert,NR,"For a patient with bladder urothelial carcinoma who has undergone mRNA TPM expression profiling from a bladder biopsy to evaluate the tumor immune microenvironment and has a tumor mutational burden of 12.0, what is the anticipated likelihood of a favorable response to atezolizumab therapy?","For a patient with bladder urothelial carcinoma who has undergone mRNA TPM expression profiling from a bladder biopsy to evaluate the tumor immune microenvironment and has a tumor mutational burden of 12.0, what is the anticipated likelihood of a favorable response to atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/4305ab-ar-4305ab9.pkl. "
BLCA,6.0,0.921568627,excluded,NR,"For a male patient with bladder urothelial carcinoma who has a tumor mutational burden of 6.0 and mRNA TPM expression analysis from a bladder biopsy evaluating the tumor immune microenvironment, how likely is a positive response to Atezolizumab therapy?","For a male patient with bladder urothelial carcinoma who has a tumor mutational burden of 6.0 and mRNA TPM expression analysis from a bladder biopsy evaluating the tumor immune microenvironment, how likely is a positive response to Atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/4501e4-ar-4501e41.pkl. "
BLCA,5.0,1.392156863,inflamed,NR,"In a male patient with bladder urothelial carcinoma, mRNA TPM expression from a biopsy was used to evaluate the tumor immune microenvironment, and the tumor mutational burden is 5.0. Based on these findings, how likely is the patient to respond to Atezolizumab therapy?","In a male patient with bladder urothelial carcinoma, mRNA TPM expression from a biopsy was used to evaluate the tumor immune microenvironment, and the tumor mutational burden is 5.0. Based on these findings, how likely is the patient to respond to Atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/45c8e6-ar-45c8e64.pkl. "
BLCA,8.0,,desert,NR,"I have a male patient with bladder urothelial carcinoma (BLCA) who underwent a nano-biopsy for mRNA TPM analysis of the tumor immune microenvironment. With a tumor mutational burden of 8.0, how likely is this patient to respond favorably to Atezolizumab therapy?","I have a male patient with bladder urothelial carcinoma (BLCA) who underwent a nano-biopsy for mRNA TPM analysis of the tumor immune microenvironment. With a tumor mutational burden of 8.0, how likely is this patient to respond favorably to Atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/468a9e-ar-468a9e1.pkl. "
BLCA,8.0,0.803921569,inflamed,NR,"In a patient with bladder urothelial carcinoma, mRNA expression profiling from a bladder biopsy was used to assess the tumor immune microenvironment, and the tumor mutational burden is measured at 8.0 mutations/Mb. Based on these findings, what is the likelihood of a favorable response to Atezolizumab therapy?","In a patient with bladder urothelial carcinoma, mRNA expression profiling from a bladder biopsy was used to assess the tumor immune microenvironment, and the tumor mutational burden is measured at 8.0 mutations/Mb. Based on these findings, what is the likelihood of a favorable response to Atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/47fc46-ar-47fc46c.pkl. "
BLCA,0.0,0.607843137,excluded,NR,"For a patient with bladder urothelial carcinoma whose tumor immune microenvironment was evaluated using mRNA TPM expression from a bladder biopsy, and who has a tumor mutational burden of 0.0, would treatment with Atezolizumab likely yield a therapeutic benefit?","For a patient with bladder urothelial carcinoma whose tumor immune microenvironment was evaluated using mRNA TPM expression from a bladder biopsy, and who has a tumor mutational burden of 0.0, would treatment with Atezolizumab likely yield a therapeutic benefit?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/49d487-ar-49d4875.pkl. "
BLCA,5.0,1.450980392,excluded,NR,"I have a male patient with bladder urothelial carcinoma whose tumor immune microenvironment was evaluated using mRNA TPM expression from a kidney biopsy. With a tumor mutational burden of 5.0, would you expect this patient to respond favorably to Atezolizumab therapy?","I have a male patient with bladder urothelial carcinoma whose tumor immune microenvironment was evaluated using mRNA TPM expression from a kidney biopsy. With a tumor mutational burden of 5.0, would you expect this patient to respond favorably to Atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/49f9b2-ar-49f9b2e.pkl. "
BLCA,6.0,,desert,NR,"In a male patient with bladder urothelial carcinoma and a tumor mutational burden of 6.0, mRNA TPM expression was assessed from a kidney biopsy to evaluate the tumor immune microenvironment. How predictive are these findings for a favorable response to Atezolizumab therapy?","In a male patient with bladder urothelial carcinoma and a tumor mutational burden of 6.0, mRNA TPM expression was assessed from a kidney biopsy to evaluate the tumor immune microenvironment. How predictive are these findings for a favorable response to Atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/4b0175-ar-4b0175e.pkl. "
BLCA,,,excluded,NR,"In a female patient with bladder urothelial carcinoma, where mRNA TPM expression from a kidney biopsy was analyzed to assess the tumor immune microenvironment and the tumor mutational burden is not available, what is the likely response to Atezolizumab therapy?","In a female patient with bladder urothelial carcinoma, where mRNA TPM expression from a kidney biopsy was analyzed to assess the tumor immune microenvironment and the tumor mutational burden is not available, what is the likely response to Atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/4b7ea0-ar-4b7ea01.pkl. "
BLCA,59.0,11.68627451,excluded,R,"For a patient with bladder urothelial carcinoma who has been evaluated using mRNA TPM expression from a ureter biopsy and has a tumor mutational burden of 59.0, how likely is it that the tumor would respond to treatment with atezolizumab?","For a patient with bladder urothelial carcinoma who has been evaluated using mRNA TPM expression from a ureter biopsy and has a tumor mutational burden of 59.0, how likely is it that the tumor would respond to treatment with atezolizumab?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/4caabd-ar-4caabd6.pkl. "
BLCA,13.0,0.31372549,desert,NR,"For a male patient with bladder urothelial carcinoma who has a tumor mutational burden of 13.0 and mRNA TPM expression data from a kidney biopsy assessing the tumor immune microenvironment, how likely is he to respond to atezolizumab therapy?","For a male patient with bladder urothelial carcinoma who has a tumor mutational burden of 13.0 and mRNA TPM expression data from a kidney biopsy assessing the tumor immune microenvironment, how likely is he to respond to atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/523468-ar-5234688.pkl. "
BLCA,12.0,0.745098039,excluded,NR,"I have a female patient with bladder urothelial carcinoma whose tumor immune microenvironment was evaluated using mRNA TPM expression from a ureter biopsy, and her tumor mutational burden is 12.0. Given these findings, do you think she is likely to benefit from treatment with atezolizumab?","I have a female patient with bladder urothelial carcinoma whose tumor immune microenvironment was evaluated using mRNA TPM expression from a ureter biopsy, and her tumor mutational burden is 12.0. Given these findings, do you think she is likely to benefit from treatment with atezolizumab?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/52500c-ar-52500ca.pkl. "
BLCA,4.0,0.254901961,,NR,"For a male patient with bladder urothelial carcinoma who had mRNA TPM expression measured from a lymph node biopsy to evaluate the tumor immune microenvironment and with a tumor mutational burden of 4.0, what is the likelihood that he will respond to treatment with atezolizumab?","For a male patient with bladder urothelial carcinoma who had mRNA TPM expression measured from a lymph node biopsy to evaluate the tumor immune microenvironment and with a tumor mutational burden of 4.0, what is the likelihood that he will respond to treatment with atezolizumab?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/52e3fa-ar-52e3fa3.pkl. "
BLCA,11.0,1.823529412,desert,R,"In a patient with bladder urothelial carcinoma (TMB = 11.0) who has undergone mRNA TPM expression profiling from a bladder biopsy to evaluate the tumor immune microenvironment, how likely is it that the patient will respond to Atezolizumab therapy?","In a patient with bladder urothelial carcinoma (TMB = 11.0) who has undergone mRNA TPM expression profiling from a bladder biopsy to evaluate the tumor immune microenvironment, how likely is it that the patient will respond to Atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/548551-ar-548551e.pkl. "
BLCA,5.0,,desert,NR,"I have a male patient with bladder urothelial carcinoma. His bladder biopsy was used to assess mRNA TPM expression as a marker of the tumor immune microenvironment, and his tumor mutational burden is 5.0. Based on these findings, is he likely to respond to Atezolizumab therapy?","I have a male patient with bladder urothelial carcinoma. His bladder biopsy was used to assess mRNA TPM expression as a marker of the tumor immune microenvironment, and his tumor mutational burden is 5.0. Based on these findings, is he likely to respond to Atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/54e58f-ar-54e58f1.pkl. "
BLCA,,,,NR,"In a female patient with bladder urothelial carcinoma, mRNA TPM expression from a kidney biopsy was used to assess the tumor immune microenvironment, and the tumor mutational burden is not available (reported as nan). Given these results, do you expect a favorable response to Atezolizumab therapy?","In a female patient with bladder urothelial carcinoma, mRNA TPM expression from a kidney biopsy was used to assess the tumor immune microenvironment, and the tumor mutational burden is not available (reported as nan). Given these results, do you expect a favorable response to Atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/553c3c-ar-553c3c3.pkl. "
BLCA,5.0,,excluded,NR,"I have a male patient diagnosed with bladder urothelial carcinoma, and his tumor immune microenvironment was evaluated using mRNA TPM expression from a ureter biopsy. With a tumor mutational burden of 5.0, would this profile be predictive of a favorable response to Atezolizumab therapy?","I have a male patient diagnosed with bladder urothelial carcinoma, and his tumor immune microenvironment was evaluated using mRNA TPM expression from a ureter biopsy. With a tumor mutational burden of 5.0, would this profile be predictive of a favorable response to Atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/557dde-ar-557dde1.pkl. "
BLCA,19.0,0.647058824,inflamed,R,"For a male patient with bladder urothelial carcinoma who has an mRNA TPM expression profile from a separate biopsy assessing the tumor immune microenvironment and a tumor mutational burden of 19.0, how likely is he to respond to Atezolizumab therapy?","For a male patient with bladder urothelial carcinoma who has an mRNA TPM expression profile from a separate biopsy assessing the tumor immune microenvironment and a tumor mutational burden of 19.0, how likely is he to respond to Atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/560f23-ar-560f23d.pkl. "
BLCA,,0.607843137,,NR,"In a male patient with bladder urothelial carcinoma, mRNA TPM expression data from a bladder biopsy has been used to assess the tumor immune microenvironment, but the tumor mutational burden (TMB) value is not available. Given these findings, how likely is the patient to respond to Atezolizumab therapy?","In a male patient with bladder urothelial carcinoma, mRNA TPM expression data from a bladder biopsy has been used to assess the tumor immune microenvironment, but the tumor mutational burden (TMB) value is not available. Given these findings, how likely is the patient to respond to Atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/563d62-ar-563d623.pkl. "
BLCA,,,,NR,"I have a female patient with bladder urothelial carcinoma, and we have analyzed her tumor mRNA TPM expression from a bladder biopsy to assess the immune microenvironment. Her tumor mutational burden is currently undetermined. Considering a trial with Atezolizumab, how might these molecular findings inform the likelihood of a favorable therapeutic response?","I have a female patient with bladder urothelial carcinoma, and we have analyzed her tumor mRNA TPM expression from a bladder biopsy to assess the immune microenvironment. Her tumor mutational burden is currently undetermined. Considering a trial with Atezolizumab, how might these molecular findings inform the likelihood of a favorable therapeutic response?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/568ce1-ar-568ce16.pkl. "
BLCA,33.0,5.509803922,excluded,R,"In a male patient with bladder urothelial carcinoma, mRNA TPM expression from a kidney biopsy was assessed to characterize the tumor immune microenvironment, and a tumor mutational burden of 33.0 was identified. Based on these findings, what is the likelihood of response to Atezolizumab therapy?","In a male patient with bladder urothelial carcinoma, mRNA TPM expression from a kidney biopsy was assessed to characterize the tumor immune microenvironment, and a tumor mutational burden of 33.0 was identified. Based on these findings, what is the likelihood of response to Atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/572f19-ar-572f197.pkl. "
BLCA,32.0,,excluded,R,"Given that this patient with bladder urothelial carcinoma has a measured mRNA TPM expression profile assessing the tumor immune microenvironment and a tumor mutational burden of 32.0, could these biomarkers indicate a favorable response to Atezolizumab?","Given that this patient with bladder urothelial carcinoma has a measured mRNA TPM expression profile assessing the tumor immune microenvironment and a tumor mutational burden of 32.0, could these biomarkers indicate a favorable response to Atezolizumab?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/5767dd-ar-5767dd7.pkl. "
BLCA,2.0,0.333333333,desert,R,"I have a male patient with bladder urothelial carcinoma (BLCA) whose tumor mutational burden is 2.0. The mRNA TPM expression was assessed from a bladder biopsy to evaluate the tumor immune microenvironment. Based on these findings, how likely is this patient to respond to Atezolizumab therapy?","I have a male patient with bladder urothelial carcinoma (BLCA) whose tumor mutational burden is 2.0. The mRNA TPM expression was assessed from a bladder biopsy to evaluate the tumor immune microenvironment. Based on these findings, how likely is this patient to respond to Atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/58e783-ar-58e7832.pkl. "
BLCA,14.0,,excluded,NR,"I have a patient with bladder urothelial carcinoma who has a tumor mutational burden of 14.0 and mRNA TPM expression analysis from a bladder biopsy indicating features of the tumor immune microenvironment. Based on these parameters, how likely is the patient to respond to Atezolizumab therapy?","I have a patient with bladder urothelial carcinoma who has a tumor mutational burden of 14.0 and mRNA TPM expression analysis from a bladder biopsy indicating features of the tumor immune microenvironment. Based on these parameters, how likely is the patient to respond to Atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/59f392-ar-59f3928.pkl. "
BLCA,,,,NR,"I have a patient with bladder urothelial carcinoma whose mRNA TPM expression was measured from a nan biopsy to evaluate the tumor immune microenvironment, and the tumor mutational burden is reported as nan. Based on these findings, what is the likelihood of a favorable response to atezolizumab therapy?","I have a patient with bladder urothelial carcinoma whose mRNA TPM expression was measured from a nan biopsy to evaluate the tumor immune microenvironment, and the tumor mutational burden is reported as nan. Based on these findings, what is the likelihood of a favorable response to atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/59fda9-ar-59fda90.pkl. "
BLCA,9.0,1.333333333,desert,NR,"In a male patient with bladder urothelial carcinoma, mRNA TPM expression from a bladder biopsy was used to assess the tumor immune microenvironment, and the tumor mutational burden is 9.0. Based on these findings, would you anticipate a favorable response to Atezolizumab?","In a male patient with bladder urothelial carcinoma, mRNA TPM expression from a bladder biopsy was used to assess the tumor immune microenvironment, and the tumor mutational burden is 9.0. Based on these findings, would you anticipate a favorable response to Atezolizumab?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/5a2347-ar-5a2347c.pkl. "
BLCA,12.0,,,NR,"I am managing a female patient with bladder urothelial carcinoma. Her tumor mutational burden is 12.0, and analysis of mRNA TPM expression from a ureter biopsy was performed to evaluate the tumor immune microenvironment. Based on these findings, what is the likelihood that she will respond to Atezolizumab treatment?","I am managing a female patient with bladder urothelial carcinoma. Her tumor mutational burden is 12.0, and analysis of mRNA TPM expression from a ureter biopsy was performed to evaluate the tumor immune microenvironment. Based on these findings, what is the likelihood that she will respond to Atezolizumab treatment?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/5b57e4-ar-5b57e47.pkl. "
BLCA,,,excluded,NR,"I have a male patient with bladder urothelial carcinoma (BLCA) whose tumor profile was assessed via mRNA TPM expression from a bladder biopsy, though the tumor mutational burden is not available. In this context, how might we predict his likelihood of responding to Atezolizumab therapy?","I have a male patient with bladder urothelial carcinoma (BLCA) whose tumor profile was assessed via mRNA TPM expression from a bladder biopsy, though the tumor mutational burden is not available. In this context, how might we predict his likelihood of responding to Atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/5c139c-ar-5c139c5.pkl. "
BLCA,11.0,0.411764706,desert,NR,"For a male patient with bladder urothelial carcinoma, whose tumor biopsy analysis shows mRNA TPM expression profiling of the immune microenvironment and a tumor mutational burden of 11.0, how might these factors influence his likelihood of responding to Atezolizumab therapy?","For a male patient with bladder urothelial carcinoma, whose tumor biopsy analysis shows mRNA TPM expression profiling of the immune microenvironment and a tumor mutational burden of 11.0, how might these factors influence his likelihood of responding to Atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/5cc2d9-ar-5cc2d90.pkl. "
BLCA,10.0,1.215686275,,NR,"I have a male patient with bladder urothelial carcinoma who underwent a liver biopsy to profile the tumor immune microenvironment, including mRNA TPM expression. With a tumor mutational burden of 10 mutations per megabase, would you expect this patient to benefit from treatment with atezolizumab?","I have a male patient with bladder urothelial carcinoma who underwent a liver biopsy to profile the tumor immune microenvironment, including mRNA TPM expression. With a tumor mutational burden of 10 mutations per megabase, would you expect this patient to benefit from treatment with atezolizumab?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/5cfa16-ar-5cfa169.pkl. "
BLCA,12.0,,,NR,"Given a male patient with bladder urothelial carcinoma (BLCA) whose tumor mRNA TPM expression profile and tumor mutational burden (TMB) of 12 have been assessed via bladder biopsy, is he likely to benefit from Atezolizumab therapy?","Given a male patient with bladder urothelial carcinoma (BLCA) whose tumor mRNA TPM expression profile and tumor mutational burden (TMB) of 12 have been assessed via bladder biopsy, is he likely to benefit from Atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/5d1dfd-ar-5d1dfd5.pkl. "
BLCA,13.0,1.411764706,desert,NR,"Given a female patient with bladder urothelial carcinoma (BLCA) who has an mRNA TPM expression profile from a bladder biopsy assessing her tumor immune microenvironment and a tumor mutational burden (TMB) of 13.0, is she likely to respond favorably to Atezolizumab therapy?","Given a female patient with bladder urothelial carcinoma (BLCA) who has an mRNA TPM expression profile from a bladder biopsy assessing her tumor immune microenvironment and a tumor mutational burden (TMB) of 13.0, is she likely to respond favorably to Atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/5d989c-ar-5d989c8.pkl. "
BLCA,6.0,0.823529412,excluded,NR,"We have a male patient with bladder urothelial carcinoma (BLCA) whose tumor mRNA TPM expression, evaluated from a kidney biopsy, was used to characterize the tumor immune microenvironment. With a tumor mutational burden (TMB) of 6.0, how likely is it that this patient will respond to treatment with atezolizumab?","We have a male patient with bladder urothelial carcinoma (BLCA) whose tumor mRNA TPM expression, evaluated from a kidney biopsy, was used to characterize the tumor immune microenvironment. With a tumor mutational burden (TMB) of 6.0, how likely is it that this patient will respond to treatment with atezolizumab?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/5e3bae-ar-5e3bae0.pkl. "
BLCA,21.0,3.823529412,inflamed,NR,"A male patient with bladder urothelial carcinoma has been evaluated using mRNA TPM expression from a ureter biopsy to assess the tumor immune microenvironment, and his tumor mutational burden is 21.0. Given these factors, is a favorable response to Atezolizumab treatment anticipated?","A male patient with bladder urothelial carcinoma has been evaluated using mRNA TPM expression from a ureter biopsy to assess the tumor immune microenvironment, and his tumor mutational burden is 21.0. Given these factors, is a favorable response to Atezolizumab treatment anticipated?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/5fe7a8-ar-5fe7a81.pkl. "
BLCA,14.0,,inflamed,R,"I have a male patient with bladder urothelial carcinoma who has undergone a bladder biopsy for mRNA TPM expression analysis of his tumor immune microenvironment. With a tumor mutational burden of 14.0, is Atezolizumab likely to be effective in this case?","I have a male patient with bladder urothelial carcinoma who has undergone a bladder biopsy for mRNA TPM expression analysis of his tumor immune microenvironment. With a tumor mutational burden of 14.0, is Atezolizumab likely to be effective in this case?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/6083aa-ar-6083aac.pkl. "
BLCA,9.0,1.803921569,desert,R,"For a male patient with bladder urothelial carcinoma (BLCA) whose tumor immune microenvironment was evaluated using mRNA TPM expression from a bladder biopsy and who has a tumor mutational burden (TMB) of 9.0, is he likely to respond favorably to Atezolizumab therapy?","For a male patient with bladder urothelial carcinoma (BLCA) whose tumor immune microenvironment was evaluated using mRNA TPM expression from a bladder biopsy and who has a tumor mutational burden (TMB) of 9.0, is he likely to respond favorably to Atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/6157c8-ar-6157c8f.pkl. "
BLCA,27.0,5.882352941,inflamed,NR,"I have a male patient with bladder urothelial carcinoma (BLCA) whose tumor mRNA TPM expression was measured via bladder biopsy to evaluate the immune microenvironment. The patient’s tumor mutation burden (TMB) is 27.0. Given these factors, how likely is it that the patient will respond favorably to Atezolizumab?","I have a male patient with bladder urothelial carcinoma (BLCA) whose tumor mRNA TPM expression was measured via bladder biopsy to evaluate the immune microenvironment. The patient’s tumor mutation burden (TMB) is 27.0. Given these factors, how likely is it that the patient will respond favorably to Atezolizumab?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/61b9d4-ar-61b9d4d.pkl. "
BLCA,,,desert,NR,"I have a female patient with bladder urothelial carcinoma, and we evaluated her tumor immune microenvironment using mRNA TPM expression from a lymph node biopsy. However, her tumor mutational burden (TMB) is not available. Given this information, how should we assess her likelihood of responding to Atezolizumab?","I have a female patient with bladder urothelial carcinoma, and we evaluated her tumor immune microenvironment using mRNA TPM expression from a lymph node biopsy. However, her tumor mutational burden (TMB) is not available. Given this information, how should we assess her likelihood of responding to Atezolizumab?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/61baf9-ar-61baf91.pkl. "
BLCA,5.0,0.784313725,,NR,"In a female patient with bladder urothelial carcinoma who underwent a kidney biopsy to evaluate mRNA TPM expression in the tumor immune microenvironment, and with a tumor mutational burden of 5.0, is there evidence to suggest a favorable response to atezolizumab therapy?","In a female patient with bladder urothelial carcinoma who underwent a kidney biopsy to evaluate mRNA TPM expression in the tumor immune microenvironment, and with a tumor mutational burden of 5.0, is there evidence to suggest a favorable response to atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/62fb13-ar-62fb138.pkl. "
BLCA,,0.156862745,,NR,"For a male patient with bladder urothelial carcinoma, where mRNA TPM expression from a bladder biopsy has been used to assess the tumor immune microenvironment and the tumor mutational burden is not quantifiable (reported as ""nan""), how should these factors influence our prediction of his response to atezolizumab therapy?","For a male patient with bladder urothelial carcinoma, where mRNA TPM expression from a bladder biopsy has been used to assess the tumor immune microenvironment and the tumor mutational burden is not quantifiable (reported as ""nan""), how should these factors influence our prediction of his response to atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/63405b-ar-63405b0.pkl. "
BLCA,14.0,0.980392157,desert,NR,"I have a male patient with bladder urothelial carcinoma whose biopsy analysis revealed mRNA expression levels (TPM) to assess the tumor immune microenvironment. The tumor mutational burden is 14.0 mutations per megabase. Given these findings, is the patient likely to benefit from treatment with atezolizumab?","I have a male patient with bladder urothelial carcinoma whose biopsy analysis revealed mRNA expression levels (TPM) to assess the tumor immune microenvironment. The tumor mutational burden is 14.0 mutations per megabase. Given these findings, is the patient likely to benefit from treatment with atezolizumab?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/63b218-ar-63b2189.pkl. "
BLCA,4.0,0.294117647,excluded,NR,"In a male patient with bladder urothelial carcinoma, a recent bladder biopsy provided mRNA TPM expression data to evaluate the tumor's immune microenvironment, and the tumor mutational burden was determined to be 4.0. Given these findings, how likely is it that the patient will respond to Atezolizumab therapy?","In a male patient with bladder urothelial carcinoma, a recent bladder biopsy provided mRNA TPM expression data to evaluate the tumor's immune microenvironment, and the tumor mutational burden was determined to be 4.0. Given these findings, how likely is it that the patient will respond to Atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/65afda-ar-65afda2.pkl. "
BLCA,5.0,0.490196078,inflamed,NR,"In a male patient with bladder urothelial carcinoma, whose bladder biopsy mRNA TPM expression data has been obtained to evaluate the tumor immune microenvironment, and who has a tumor mutational burden of 5.0, would you anticipate a favorable response to atezolizumab therapy?","In a male patient with bladder urothelial carcinoma, whose bladder biopsy mRNA TPM expression data has been obtained to evaluate the tumor immune microenvironment, and who has a tumor mutational burden of 5.0, would you anticipate a favorable response to atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/6662f5-ar-6662f51.pkl. "
BLCA,15.0,2.68627451,excluded,R,"In a female patient with bladder urothelial carcinoma who has a tumor mutational burden of 15.0 and mRNA TPM expression data from a bladder biopsy assessing the tumor immune microenvironment, how likely is she to benefit from treatment with Atezolizumab?","In a female patient with bladder urothelial carcinoma who has a tumor mutational burden of 15.0 and mRNA TPM expression data from a bladder biopsy assessing the tumor immune microenvironment, how likely is she to benefit from treatment with Atezolizumab?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/670649-ar-670649e.pkl. "
BLCA,13.0,1.254901961,desert,NR,"In a male patient with bladder urothelial carcinoma, whose bladder biopsy shows mRNA TPM expression patterns indicative of the tumor immune microenvironment and a tumor mutational burden of 13.0, would treatment with Atezolizumab likely result in a favorable response?","In a male patient with bladder urothelial carcinoma, whose bladder biopsy shows mRNA TPM expression patterns indicative of the tumor immune microenvironment and a tumor mutational burden of 13.0, would treatment with Atezolizumab likely result in a favorable response?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/675a12-ar-675a12a.pkl. "
BLCA,14.0,2.549019608,inflamed,NR,"In a female patient with bladder urothelial carcinoma, who has undergone a bladder biopsy with mRNA TPM expression profiling to assess the tumor immune microenvironment and presents with a tumor mutational burden of 14.0, what is the predicted likelihood of a positive response to Atezolizumab therapy?","In a female patient with bladder urothelial carcinoma, who has undergone a bladder biopsy with mRNA TPM expression profiling to assess the tumor immune microenvironment and presents with a tumor mutational burden of 14.0, what is the predicted likelihood of a positive response to Atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/6780ed-ar-6780ed4.pkl. "
BLCA,17.0,1.117647059,desert,NR,"In a male patient with bladder urothelial carcinoma, whose biopsy reveals mRNA TPM expression of the tumor immune microenvironment and a tumor mutational burden of 17.0, how likely is it that the patient will respond favorably to Atezolizumab?","In a male patient with bladder urothelial carcinoma, whose biopsy reveals mRNA TPM expression of the tumor immune microenvironment and a tumor mutational burden of 17.0, how likely is it that the patient will respond favorably to Atezolizumab?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/6792d6-ar-6792d6e.pkl. "
BLCA,7.0,1.862745098,excluded,R,"I have a male patient with bladder urothelial carcinoma whose mRNA TPM expression has been measured from a bladder biopsy to evaluate the tumor immune microenvironment. The tumor mutational burden is 7.0. Based on these factors, what is the likelihood that this patient will respond to Atezolizumab therapy?","I have a male patient with bladder urothelial carcinoma whose mRNA TPM expression has been measured from a bladder biopsy to evaluate the tumor immune microenvironment. The tumor mutational burden is 7.0. Based on these factors, what is the likelihood that this patient will respond to Atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/681e4b-ar-681e4bf.pkl. "
BLCA,5.0,1.176470588,,NR,"I have a male patient with bladder urothelial carcinoma who underwent a bladder biopsy, and we measured mRNA TPM levels to evaluate the tumor immune microenvironment. With a tumor mutational burden of 5.0, how likely is it that the patient will respond to Atezolizumab therapy?","I have a male patient with bladder urothelial carcinoma who underwent a bladder biopsy, and we measured mRNA TPM levels to evaluate the tumor immune microenvironment. With a tumor mutational burden of 5.0, how likely is it that the patient will respond to Atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/6964a6-ar-6964a6d.pkl. "
BLCA,20.0,1.039215686,desert,R,"I have a patient with bladder urothelial carcinoma whose tumor mutational burden is 20.0. mRNA TPM expression from a lung biopsy was obtained to assess the tumor immune microenvironment. Based on these findings, how likely is the patient to respond to atezolizumab therapy?","I have a patient with bladder urothelial carcinoma whose tumor mutational burden is 20.0. mRNA TPM expression from a lung biopsy was obtained to assess the tumor immune microenvironment. Based on these findings, how likely is the patient to respond to atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/6cb230-ar-6cb230f.pkl. "
BLCA,3.0,0.960784314,inflamed,NR,"In a male patient with bladder urothelial carcinoma who underwent a bladder biopsy for mRNA TPM assessment of the tumor immune microenvironment, the tumor exhibits a mutational burden of 3.0. Based on these factors, what is the anticipated likelihood of a favorable response to atezolizumab therapy?","In a male patient with bladder urothelial carcinoma who underwent a bladder biopsy for mRNA TPM assessment of the tumor immune microenvironment, the tumor exhibits a mutational burden of 3.0. Based on these factors, what is the anticipated likelihood of a favorable response to atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/6cbc10-ar-6cbc10a.pkl. "
BLCA,,,excluded,NR,"I have a male patient with bladder urothelial carcinoma (BLCA), and we assessed his tumor immune microenvironment using mRNA TPM expression from a lymph node biopsy. However, his tumor mutational burden (TMB) is not available. Given these details, what is the likelihood that he will respond favorably to atezolizumab therapy?","I have a male patient with bladder urothelial carcinoma (BLCA), and we assessed his tumor immune microenvironment using mRNA TPM expression from a lymph node biopsy. However, his tumor mutational burden (TMB) is not available. Given these details, what is the likelihood that he will respond favorably to atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/6d2ae0-ar-6d2ae0c.pkl. "
BLCA,,3.568627451,,NR,"For a male patient with bladder urothelial carcinoma, where mRNA TPM expression from a bladder biopsy was analyzed to evaluate the tumor immune microenvironment and the tumor mutational burden (TMB) is not available, what is the likelihood of a favorable response to Atezolizumab therapy?","For a male patient with bladder urothelial carcinoma, where mRNA TPM expression from a bladder biopsy was analyzed to evaluate the tumor immune microenvironment and the tumor mutational burden (TMB) is not available, what is the likelihood of a favorable response to Atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/6dd7ad-ar-6dd7ad1.pkl. "
BLCA,8.0,2.078431373,,R,"I have a female patient with bladder urothelial carcinoma who underwent a nano-biopsy to assess mRNA TPM expression in the tumor immune microenvironment. The tumor's mutational burden is 8.0. Based on these factors, would you anticipate a favorable response to atezolizumab therapy?","I have a female patient with bladder urothelial carcinoma who underwent a nano-biopsy to assess mRNA TPM expression in the tumor immune microenvironment. The tumor's mutational burden is 8.0. Based on these factors, would you anticipate a favorable response to atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/6f2a10-ar-6f2a102.pkl. "
BLCA,6.0,1.039215686,excluded,R,"For a male patient with bladder urothelial carcinoma, a tumor mutational burden of 6.0, and mRNA TPM expression measured from a kidney biopsy to evaluate the tumor immune microenvironment, how likely is he to respond to atezolizumab therapy?","For a male patient with bladder urothelial carcinoma, a tumor mutational burden of 6.0, and mRNA TPM expression measured from a kidney biopsy to evaluate the tumor immune microenvironment, how likely is he to respond to atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/6ff654-ar-6ff654a.pkl. "
BLCA,17.0,2.176470588,,NR,"I have a male patient with bladder urothelial carcinoma whose tumor was analyzed using mRNA TPM expression from a bladder biopsy to assess the immune microenvironment, and his tumor mutational burden is 17 mutations per megabase. Given these findings, is he likely to respond favorably to atezolizumab therapy?","I have a male patient with bladder urothelial carcinoma whose tumor was analyzed using mRNA TPM expression from a bladder biopsy to assess the immune microenvironment, and his tumor mutational burden is 17 mutations per megabase. Given these findings, is he likely to respond favorably to atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/7114d9-ar-7114d99.pkl. "
BLCA,6.0,1.568627451,,NR,"Given the patient's bladder urothelial carcinoma, mRNA TPM expression profile obtained from a kidney biopsy to evaluate the tumor immune microenvironment, and a tumor mutational burden of 6.0, is it likely that they would respond to Atezolizumab therapy?","Given the patient's bladder urothelial carcinoma, mRNA TPM expression profile obtained from a kidney biopsy to evaluate the tumor immune microenvironment, and a tumor mutational burden of 6.0, is it likely that they would respond to Atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/716f54-ar-716f54e.pkl. "
BLCA,1.0,0.333333333,,R,"In a male patient with bladder urothelial carcinoma and a tumor mutational burden of 1.0, where mRNA TPM expression has been assessed from a lymph node biopsy to evaluate the tumor immune microenvironment, how likely is it that he will respond to atezolizumab therapy?","In a male patient with bladder urothelial carcinoma and a tumor mutational burden of 1.0, where mRNA TPM expression has been assessed from a lymph node biopsy to evaluate the tumor immune microenvironment, how likely is it that he will respond to atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/727c0e-ar-727c0e9.pkl. "
BLCA,,,excluded,R,"In a male patient diagnosed with bladder urothelial carcinoma, we have evaluated the tumor immune microenvironment using mRNA TPM expression from a kidney biopsy, though his tumor mutational burden is not available. Given this information, how likely is he to respond to treatment with atezolizumab?","In a male patient diagnosed with bladder urothelial carcinoma, we have evaluated the tumor immune microenvironment using mRNA TPM expression from a kidney biopsy, though his tumor mutational burden is not available. Given this information, how likely is he to respond to treatment with atezolizumab?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/73663e-ar-73663ee.pkl. "
BLCA,7.0,0.274509804,excluded,NR,"A female patient with bladder urothelial carcinoma underwent a kidney biopsy for mRNA TPM expression profiling to evaluate her tumor immune microenvironment, and her tumor mutational burden is 7.0. Based on these findings, is she likely to respond favorably to Atezolizumab therapy?","A female patient with bladder urothelial carcinoma underwent a kidney biopsy for mRNA TPM expression profiling to evaluate her tumor immune microenvironment, and her tumor mutational burden is 7.0. Based on these findings, is she likely to respond favorably to Atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/75142f-ar-75142fc.pkl. "
BLCA,21.0,2.392156863,inflamed,NR,"I have a female patient with bladder urothelial carcinoma whose mRNA TPM expression was evaluated from a bladder biopsy to assess the tumor immune microenvironment, and her tumor mutational burden is 21.0. Based on these findings, is she likely to respond to Atezolizumab therapy?","I have a female patient with bladder urothelial carcinoma whose mRNA TPM expression was evaluated from a bladder biopsy to assess the tumor immune microenvironment, and her tumor mutational burden is 21.0. Based on these findings, is she likely to respond to Atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/7538ad-ar-7538ad9.pkl. "
BLCA,7.0,,excluded,NR,"For a male patient with bladder urothelial carcinoma, whose tumor microenvironment has been characterized by mRNA TPM expression from a ureter biopsy and who exhibits a tumor mutational burden of 7.0, would Atezolizumab likely be an effective treatment option?","For a male patient with bladder urothelial carcinoma, whose tumor microenvironment has been characterized by mRNA TPM expression from a ureter biopsy and who exhibits a tumor mutational burden of 7.0, would Atezolizumab likely be an effective treatment option?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/753d4b-ar-753d4bb.pkl. "
BLCA,6.0,0.333333333,inflamed,NR,"In a patient with bladder urothelial carcinoma whose lung biopsy analysis shows specific mRNA TPM expression profiles and a tumor mutational burden of 6.0, how likely is it that treatment with atezolizumab would be effective in modulating the tumor immune microenvironment?","In a patient with bladder urothelial carcinoma whose lung biopsy analysis shows specific mRNA TPM expression profiles and a tumor mutational burden of 6.0, how likely is it that treatment with atezolizumab would be effective in modulating the tumor immune microenvironment?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/75f12d-ar-75f12d1.pkl. "
BLCA,6.0,0.215686275,inflamed,NR,"A 60-year-old patient with bladder urothelial carcinoma underwent a kidney biopsy for mRNA TPM expression analysis of the tumor immune microenvironment. With a tumor mutational burden of 6.0, would this patient be expected to respond favorably to atezolizumab therapy?","A 60-year-old patient with bladder urothelial carcinoma underwent a kidney biopsy for mRNA TPM expression analysis of the tumor immune microenvironment. With a tumor mutational burden of 6.0, would this patient be expected to respond favorably to atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/76a431-ar-76a431b.pkl. "
BLCA,,0.215686275,inflamed,R,"In a patient with bladder urothelial carcinoma, where mRNA TPM expression from a bladder biopsy has been used to characterize the tumor immune microenvironment and the tumor mutational burden is reported as ‘nan’, what is the likelihood that the patient will respond to Atezolizumab therapy?","In a patient with bladder urothelial carcinoma, where mRNA TPM expression from a bladder biopsy has been used to characterize the tumor immune microenvironment and the tumor mutational burden is reported as ‘nan’, what is the likelihood that the patient will respond to Atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/771445-ar-771445e.pkl. "
BLCA,3.0,0.745098039,inflamed,NR,"Given a bladder urothelial carcinoma patient whose tumor biopsy revealed mRNA TPM expression profiling of the immune microenvironment and a tumor mutational burden of 3.0, would treatment with atezolizumab be expected to yield a favorable response?","Given a bladder urothelial carcinoma patient whose tumor biopsy revealed mRNA TPM expression profiling of the immune microenvironment and a tumor mutational burden of 3.0, would treatment with atezolizumab be expected to yield a favorable response?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/7829a3-ar-7829a34.pkl. "
BLCA,5.0,0.941176471,,NR,"For a male patient with bladder urothelial carcinoma, where the tumor mRNA expression (TPM) from a bladder biopsy was used to assess the immune microenvironment and a tumor mutational burden (TMB) of 5.0 was determined, is he likely to benefit from Atezolizumab therapy?","For a male patient with bladder urothelial carcinoma, where the tumor mRNA expression (TPM) from a bladder biopsy was used to assess the immune microenvironment and a tumor mutational burden (TMB) of 5.0 was determined, is he likely to benefit from Atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/789319-ar-7893196.pkl. "
BLCA,,1.039215686,excluded,NR,"In a male patient with bladder urothelial carcinoma, mRNA TPM expression profiling from a bladder biopsy was performed to characterize the tumor immune microenvironment, while the tumor mutational burden is not available. How might these findings influence the predicted response to Atezolizumab therapy?","In a male patient with bladder urothelial carcinoma, mRNA TPM expression profiling from a bladder biopsy was performed to characterize the tumor immune microenvironment, while the tumor mutational burden is not available. How might these findings influence the predicted response to Atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/7aa01f-ar-7aa01fc.pkl. "
BLCA,12.0,,,R,"In a female patient with bladder urothelial carcinoma, whose tumor mutational burden is 12.0 and whose tumor immune microenvironment was evaluated via mRNA TPM expression from a ureter biopsy, would you expect a favorable response to atezolizumab therapy?","In a female patient with bladder urothelial carcinoma, whose tumor mutational burden is 12.0 and whose tumor immune microenvironment was evaluated via mRNA TPM expression from a ureter biopsy, would you expect a favorable response to atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/7b4000-ar-7b40007.pkl. "
BLCA,,0.725490196,,NR,"I have a male patient with bladder urothelial carcinoma. We measured his tumor mRNA TPM expression from a ureter biopsy to evaluate the immune microenvironment, but his tumor mutational burden data is not available. Based on these findings, what can be inferred about his potential response to atezolizumab?","I have a male patient with bladder urothelial carcinoma. We measured his tumor mRNA TPM expression from a ureter biopsy to evaluate the immune microenvironment, but his tumor mutational burden data is not available. Based on these findings, what can be inferred about his potential response to atezolizumab?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/7bff23-ar-7bff231.pkl. "
BLCA,5.0,0.529411765,,NR,"In a female patient with bladder urothelial carcinoma, whose tumor immune microenvironment was characterized by mRNA TPM expression from a bladder biopsy and who has a tumor mutational burden of 5.0, would Atezolizumab be an effective treatment option?","In a female patient with bladder urothelial carcinoma, whose tumor immune microenvironment was characterized by mRNA TPM expression from a bladder biopsy and who has a tumor mutational burden of 5.0, would Atezolizumab be an effective treatment option?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/7c67b0-ar-7c67b05.pkl. "
BLCA,4.0,0.156862745,inflamed,NR,"In a male patient with bladder urothelial carcinoma, mRNA TPM expression analysis from a lymph node biopsy was used to assess the tumor immune microenvironment, and the tumor mutational burden is 4.0. Considering these factors, what is the likelihood that the patient will respond to Atezolizumab therapy?","In a male patient with bladder urothelial carcinoma, mRNA TPM expression analysis from a lymph node biopsy was used to assess the tumor immune microenvironment, and the tumor mutational burden is 4.0. Considering these factors, what is the likelihood that the patient will respond to Atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/7d2dfb-ar-7d2dfba.pkl. "
BLCA,8.0,2.098039216,excluded,R,"In a patient with bladder urothelial carcinoma, mRNA TPM expression from a bladder biopsy has been used to characterize the tumor immune microenvironment, and the tumor mutational burden is 8.0. How likely is it that the patient will respond to Atezolizumab therapy?","In a patient with bladder urothelial carcinoma, mRNA TPM expression from a bladder biopsy has been used to characterize the tumor immune microenvironment, and the tumor mutational burden is 8.0. How likely is it that the patient will respond to Atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/7d7c54-ar-7d7c546.pkl. "
BLCA,,,excluded,NR,"I have a patient with bladder urothelial carcinoma whose tumor immune microenvironment was evaluated via mRNA TPM expression from a bladder biopsy, but the tumor mutational burden data is not available. Given these findings, how might we assess the likelihood of a positive response to Atezolizumab?","I have a patient with bladder urothelial carcinoma whose tumor immune microenvironment was evaluated via mRNA TPM expression from a bladder biopsy, but the tumor mutational burden data is not available. Given these findings, how might we assess the likelihood of a positive response to Atezolizumab?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/7f0d9c-ar-7f0d9cc.pkl. "
BLCA,1.0,,excluded,NR,"I have a male patient with bladder urothelial carcinoma whose bladder biopsy revealed mRNA TPM expression, and the tumor has a mutational burden of 1.0. Given these findings, would you expect the patient to respond favorably to treatment with Atezolizumab?","I have a male patient with bladder urothelial carcinoma whose bladder biopsy revealed mRNA TPM expression, and the tumor has a mutational burden of 1.0. Given these findings, would you expect the patient to respond favorably to treatment with Atezolizumab?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/7fb698-ar-7fb6987.pkl. "
BLCA,11.0,0.764705882,excluded,NR,"We have a male patient with bladder urothelial carcinoma whose tumor mRNA TPM expression was measured from a kidney biopsy to evaluate the immune microenvironment, and his tumor mutational burden is 11.0. Based on these findings, how likely is it that he will respond to Atezolizumab therapy?","We have a male patient with bladder urothelial carcinoma whose tumor mRNA TPM expression was measured from a kidney biopsy to evaluate the immune microenvironment, and his tumor mutational burden is 11.0. Based on these findings, how likely is it that he will respond to Atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/7fb7a1-ar-7fb7a13.pkl. "
BLCA,8.0,0.215686275,inflamed,NR,"For a male patient with bladder urothelial carcinoma, mRNA TPM expression profiling from a kidney biopsy was used to evaluate the tumor immune microenvironment, and the tumor mutational burden is 8.0. Given these parameters, is there evidence to suggest that the patient is likely to respond to treatment with atezolizumab?","For a male patient with bladder urothelial carcinoma, mRNA TPM expression profiling from a kidney biopsy was used to evaluate the tumor immune microenvironment, and the tumor mutational burden is 8.0. Given these parameters, is there evidence to suggest that the patient is likely to respond to treatment with atezolizumab?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/80c618-ar-80c6183.pkl. "
BLCA,7.0,1.078431373,,NR,"In a female patient with bladder urothelial carcinoma, a bladder biopsy was performed to assess the tumor immune microenvironment through mRNA TPM expression analysis, and the tumor mutational burden is 7.0. Based on these findings, is the patient likely to respond to atezolizumab therapy?","In a female patient with bladder urothelial carcinoma, a bladder biopsy was performed to assess the tumor immune microenvironment through mRNA TPM expression analysis, and the tumor mutational burden is 7.0. Based on these findings, is the patient likely to respond to atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/81b715-ar-81b7152.pkl. "
BLCA,,1.098039216,desert,NR,"I have a male patient with bladder urothelial carcinoma. His tumor mRNA TPM expression was analyzed from a separate biopsy to evaluate the immune microenvironment, and his tumor mutational burden (TMB) is not available. Given these details, how likely is it that he will respond to Atezolizumab therapy?","I have a male patient with bladder urothelial carcinoma. His tumor mRNA TPM expression was analyzed from a separate biopsy to evaluate the immune microenvironment, and his tumor mutational burden (TMB) is not available. Given these details, how likely is it that he will respond to Atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/822b22-ar-822b226.pkl. "
BLCA,5.0,1.725490196,desert,R,"In a male patient with bladder urothelial carcinoma, mRNA TPM expression from a bladder biopsy was analyzed to evaluate the tumor immune microenvironment, and the tumor mutational burden is 5.0. Based on this information, is treatment with atezolizumab likely to be effective?","In a male patient with bladder urothelial carcinoma, mRNA TPM expression from a bladder biopsy was analyzed to evaluate the tumor immune microenvironment, and the tumor mutational burden is 5.0. Based on this information, is treatment with atezolizumab likely to be effective?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/8533e5-ar-8533e5e.pkl. "
BLCA,8.0,0.274509804,excluded,NR,"For a male patient with bladder urothelial carcinoma who has a tumor mutational burden of 8.0 and whose mRNA TPM expression was measured from a lung biopsy to assess the tumor immune microenvironment, how likely is it that he will respond favorably to Atezolizumab therapy?","For a male patient with bladder urothelial carcinoma who has a tumor mutational burden of 8.0 and whose mRNA TPM expression was measured from a lung biopsy to assess the tumor immune microenvironment, how likely is it that he will respond favorably to Atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/85f0a3-ar-85f0a3a.pkl. "
BLCA,14.0,0.31372549,excluded,NR,"In a female patient with bladder urothelial carcinoma who has a tumor mutational burden of 14.0 and mRNA TPM expression data from a bladder biopsy evaluating the tumor immune microenvironment, is treatment with Atezolizumab likely to be effective?","In a female patient with bladder urothelial carcinoma who has a tumor mutational burden of 14.0 and mRNA TPM expression data from a bladder biopsy evaluating the tumor immune microenvironment, is treatment with Atezolizumab likely to be effective?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/87a8e1-ar-87a8e18.pkl. "
BLCA,13.0,6.0,inflamed,R,"In a male patient with bladder urothelial carcinoma who has undergone a bladder biopsy demonstrating mRNA TPM expression profiling of the tumor immune microenvironment, and with a tumor mutational burden of 13.0, how likely is he to respond to treatment with Atezolizumab?","In a male patient with bladder urothelial carcinoma who has undergone a bladder biopsy demonstrating mRNA TPM expression profiling of the tumor immune microenvironment, and with a tumor mutational burden of 13.0, how likely is he to respond to treatment with Atezolizumab?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/8884fe-ar-8884fe4.pkl. "
BLCA,14.0,0.843137255,desert,R,"I have a male patient with bladder urothelial carcinoma (BLCA) whose mRNA TPM expression was assessed from a bladder biopsy to evaluate the tumor immune microenvironment. With a tumor mutational burden of 14 mutations per megabase, how likely is this patient to benefit from Atezolizumab therapy?","I have a male patient with bladder urothelial carcinoma (BLCA) whose mRNA TPM expression was assessed from a bladder biopsy to evaluate the tumor immune microenvironment. With a tumor mutational burden of 14 mutations per megabase, how likely is this patient to benefit from Atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/8a1b0e-ar-8a1b0e0.pkl. "
BLCA,7.0,1.0,excluded,NR,"I have a male patient with bladder urothelial carcinoma (BLCA) for whom mRNA TPM expression was measured from a kidney biopsy to evaluate the tumor immune microenvironment, and the tumor mutational burden is 7.0. Based on these findings, how likely is it that the patient will respond to atezolizumab therapy?","I have a male patient with bladder urothelial carcinoma (BLCA) for whom mRNA TPM expression was measured from a kidney biopsy to evaluate the tumor immune microenvironment, and the tumor mutational burden is 7.0. Based on these findings, how likely is it that the patient will respond to atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/8b4b8b-ar-8b4b8b0.pkl. "
BLCA,6.0,,excluded,NR,"For a male patient with bladder urothelial carcinoma, a bladder biopsy shows mRNA TPM expression data reflecting the tumor immune microenvironment, and the tumor mutational burden is 6.0. Based on these findings, would you anticipate a favorable response to Atezolizumab therapy?","For a male patient with bladder urothelial carcinoma, a bladder biopsy shows mRNA TPM expression data reflecting the tumor immune microenvironment, and the tumor mutational burden is 6.0. Based on these findings, would you anticipate a favorable response to Atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/8e4698-ar-8e46983.pkl. "
BLCA,6.0,0.509803922,desert,NR,"I am evaluating a male patient with bladder urothelial carcinoma. The tumor’s immune microenvironment was assessed using mRNA TPM expression obtained from a kidney biopsy, and the tumor mutational burden is 6.0. Based on these findings, what is the likelihood that the patient will respond to Atezolizumab therapy?","I am evaluating a male patient with bladder urothelial carcinoma. The tumor’s immune microenvironment was assessed using mRNA TPM expression obtained from a kidney biopsy, and the tumor mutational burden is 6.0. Based on these findings, what is the likelihood that the patient will respond to Atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/8e8ef2-ar-8e8ef23.pkl. "
BLCA,5.0,,desert,NR,"In a male patient with bladder urothelial carcinoma, mRNA TPM expression from a bladder biopsy was used to characterize the tumor immune microenvironment, and the tumor mutational burden is 5.0. Based on these factors, what is the likelihood of a positive response to Atezolizumab therapy?","In a male patient with bladder urothelial carcinoma, mRNA TPM expression from a bladder biopsy was used to characterize the tumor immune microenvironment, and the tumor mutational burden is 5.0. Based on these factors, what is the likelihood of a positive response to Atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/8f2275-ar-8f2275c.pkl. "
BLCA,49.0,2.705882353,inflamed,R,"In a male patient with bladder urothelial carcinoma who has a tumor mutational burden of 49.0 and mRNA TPM expression measured from a bladder biopsy to assess the tumor immune microenvironment, do these parameters suggest that treatment with Atezolizumab is likely to be effective?","In a male patient with bladder urothelial carcinoma who has a tumor mutational burden of 49.0 and mRNA TPM expression measured from a bladder biopsy to assess the tumor immune microenvironment, do these parameters suggest that treatment with Atezolizumab is likely to be effective?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/91c47b-ar-91c47b0.pkl. "
BLCA,12.0,2.235294118,inflamed,NR,"In a patient with bladder urothelial carcinoma, whose bladder biopsy shows mRNA TPM expression analyzed to assess the tumor immune microenvironment and who has a tumor mutational burden of 12.0, how likely is a positive response to atezolizumab?","In a patient with bladder urothelial carcinoma, whose bladder biopsy shows mRNA TPM expression analyzed to assess the tumor immune microenvironment and who has a tumor mutational burden of 12.0, how likely is a positive response to atezolizumab?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/9306c5-ar-9306c5c.pkl. "
BLCA,,,,NR,"For a patient with bladder urothelial carcinoma who has undergone mRNA TPM expression profiling from a bladder biopsy to assess the tumor immune microenvironment, and whose tumor mutational burden is not clearly quantified (reported as nan), would you anticipate a favorable response to treatment with Atezolizumab based on these findings?","For a patient with bladder urothelial carcinoma who has undergone mRNA TPM expression profiling from a bladder biopsy to assess the tumor immune microenvironment, and whose tumor mutational burden is not clearly quantified (reported as nan), would you anticipate a favorable response to treatment with Atezolizumab based on these findings?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/9410b8-ar-9410b86.pkl. "
BLCA,5.0,0.117647059,desert,NR,"For a male patient with bladder urothelial carcinoma, with mRNA TPM expression assessed from a bladder biopsy to evaluate the tumor immune microenvironment and a tumor mutational burden of 5.0, is Atezolizumab likely to be effective as a treatment?","For a male patient with bladder urothelial carcinoma, with mRNA TPM expression assessed from a bladder biopsy to evaluate the tumor immune microenvironment and a tumor mutational burden of 5.0, is Atezolizumab likely to be effective as a treatment?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/943df5-ar-943df5c.pkl. "
BLCA,11.0,0.215686275,excluded,NR,"For a male patient with bladder urothelial carcinoma whose mRNA TPM expression was assessed via kidney biopsy and who has a tumor mutational burden of 11.0, is Atezolizumab likely to be an effective treatment option?","For a male patient with bladder urothelial carcinoma whose mRNA TPM expression was assessed via kidney biopsy and who has a tumor mutational burden of 11.0, is Atezolizumab likely to be an effective treatment option?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/94859b-ar-94859b4.pkl. "
BLCA,,0.431372549,desert,NR,"I have a male patient with bladder urothelial carcinoma who underwent a bladder biopsy, and we have mRNA TPM expression data to evaluate the tumor immune microenvironment. However, the tumor mutational burden data is not available (nan). Based on these findings, how likely is the patient to respond to Atezolizumab therapy?","I have a male patient with bladder urothelial carcinoma who underwent a bladder biopsy, and we have mRNA TPM expression data to evaluate the tumor immune microenvironment. However, the tumor mutational burden data is not available (nan). Based on these findings, how likely is the patient to respond to Atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/9539a4-ar-9539a4f.pkl. "
BLCA,,0.196078431,excluded,NR,"I have a male patient with bladder urothelial carcinoma. mRNA TPM expression was assessed from a ureter biopsy to evaluate the tumor immune microenvironment, and the tumor mutational burden is reported as 'nan'. Based on these findings, how likely is the patient to benefit from atezolizumab therapy?","I have a male patient with bladder urothelial carcinoma. mRNA TPM expression was assessed from a ureter biopsy to evaluate the tumor immune microenvironment, and the tumor mutational burden is reported as 'nan'. Based on these findings, how likely is the patient to benefit from atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/957378-ar-957378b.pkl. "
BLCA,17.0,1.725490196,excluded,NR,"In a male patient with bladder urothelial carcinoma, whose tumor biopsy reveals specific mRNA TPM expression profiling of the immune microenvironment and a tumor mutational burden of 17.0, would you predict a favorable response to Atezolizumab therapy?","In a male patient with bladder urothelial carcinoma, whose tumor biopsy reveals specific mRNA TPM expression profiling of the immune microenvironment and a tumor mutational burden of 17.0, would you predict a favorable response to Atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/961d04-ar-961d04c.pkl. "
BLCA,22.0,4.431372549,desert,NR,"Given a male patient with bladder urothelial carcinoma who underwent a bladder biopsy with mRNA TPM expression analysis of the tumor immune microenvironment and has a tumor mutational burden of 22.0, how likely is he to respond to Atezolizumab therapy?","Given a male patient with bladder urothelial carcinoma who underwent a bladder biopsy with mRNA TPM expression analysis of the tumor immune microenvironment and has a tumor mutational burden of 22.0, how likely is he to respond to Atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/972530-ar-9725303.pkl. "
BLCA,,1.921568627,excluded,NR,"A patient with bladder urothelial carcinoma had a bladder biopsy for mRNA TPM expression profiling to evaluate the tumor immune microenvironment, and the tumor mutational burden is reported as ""nan."" Based on this information, what is the likelihood that the patient will respond to Atezolizumab therapy?","A patient with bladder urothelial carcinoma had a bladder biopsy for mRNA TPM expression profiling to evaluate the tumor immune microenvironment, and the tumor mutational burden is reported as ""nan."" Based on this information, what is the likelihood that the patient will respond to Atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/978a58-ar-978a587.pkl. "
BLCA,18.0,2.862745098,excluded,R,"In a male patient with bladder urothelial carcinoma, mRNA TPM expression from a kidney biopsy was used to evaluate the tumor immune microenvironment, and his tumor mutational burden (TMB) is 18.0. Given these findings, what is the likelihood that he will respond to Atezolizumab therapy?","In a male patient with bladder urothelial carcinoma, mRNA TPM expression from a kidney biopsy was used to evaluate the tumor immune microenvironment, and his tumor mutational burden (TMB) is 18.0. Given these findings, what is the likelihood that he will respond to Atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/97a00e-ar-97a00e0.pkl. "
BLCA,5.0,0.725490196,excluded,NR,"In a male patient with bladder urothelial carcinoma (BLCA) who has undergone kidney biopsy with mRNA TPM expression analysis to evaluate the tumor immune microenvironment and has a tumor mutational burden (TMB) of 5.0, how likely is it that he will respond to atezolizumab therapy?","In a male patient with bladder urothelial carcinoma (BLCA) who has undergone kidney biopsy with mRNA TPM expression analysis to evaluate the tumor immune microenvironment and has a tumor mutational burden (TMB) of 5.0, how likely is it that he will respond to atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/99a46b-ar-99a46b9.pkl. "
BLCA,4.0,0.862745098,inflamed,NR,"I have a male patient with bladder urothelial carcinoma whose tumor immune microenvironment was assessed via mRNA TPM expression from a bladder biopsy, and his tumor mutational burden is 4.0 mutations per megabase. Considering the initiation of Atezolizumab, how likely is he to respond based on these findings?","I have a male patient with bladder urothelial carcinoma whose tumor immune microenvironment was assessed via mRNA TPM expression from a bladder biopsy, and his tumor mutational burden is 4.0 mutations per megabase. Considering the initiation of Atezolizumab, how likely is he to respond based on these findings?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/9a2cf3-ar-9a2cf3c.pkl. "
BLCA,5.0,0.647058824,excluded,NR,"For a male patient with bladder urothelial carcinoma (BLCA) whose tumor immune microenvironment was evaluated using mRNA TPM expression from a kidney biopsy and who has a tumor mutational burden of 5.0, how likely is it that he will respond to Atezolizumab therapy?","For a male patient with bladder urothelial carcinoma (BLCA) whose tumor immune microenvironment was evaluated using mRNA TPM expression from a kidney biopsy and who has a tumor mutational burden of 5.0, how likely is it that he will respond to Atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/9aa6a0-ar-9aa6a09.pkl. "
BLCA,12.0,0.588235294,inflamed,NR,"I have a male patient with bladder urothelial carcinoma. A kidney biopsy was performed to measure mRNA TPM expression for assessing the tumor immune microenvironment, and the tumor mutational burden is 12.0 mutations per megabase. Given these factors, would you expect this patient to respond favorably to Atezolizumab?","I have a male patient with bladder urothelial carcinoma. A kidney biopsy was performed to measure mRNA TPM expression for assessing the tumor immune microenvironment, and the tumor mutational burden is 12.0 mutations per megabase. Given these factors, would you expect this patient to respond favorably to Atezolizumab?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/9cafb9-ar-9cafb90.pkl. "
BLCA,,,,NR,"I have a male patient with bladder urothelial carcinoma, and we recently analyzed his tumor immune microenvironment using mRNA TPM expression from a liver biopsy. Although his tumor mutational burden is currently undetermined, would you anticipate that he is likely to respond to Atezolizumab therapy?","I have a male patient with bladder urothelial carcinoma, and we recently analyzed his tumor immune microenvironment using mRNA TPM expression from a liver biopsy. Although his tumor mutational burden is currently undetermined, would you anticipate that he is likely to respond to Atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/9d2494-ar-9d24941.pkl. "
BLCA,,,desert,NR,"A female patient with bladder urothelial carcinoma (BLCA) underwent a kidney biopsy for mRNA TPM expression profiling to assess the tumor immune microenvironment. With a reported tumor mutational burden (TMB) of ""nan"" and considering treatment with Atezolizumab, would this patient be expected to respond favorably to immune checkpoint inhibition?","A female patient with bladder urothelial carcinoma (BLCA) underwent a kidney biopsy for mRNA TPM expression profiling to assess the tumor immune microenvironment. With a reported tumor mutational burden (TMB) of ""nan"" and considering treatment with Atezolizumab, would this patient be expected to respond favorably to immune checkpoint inhibition?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/9dacca-ar-9daccaf.pkl. "
BLCA,10.0,,inflamed,NR,"In a male patient with bladder urothelial carcinoma (BLCA), a tumor mutational burden of 10.0, and mRNA TPM expression profiling from a bladder biopsy to evaluate the tumor immune microenvironment, what is the likelihood of a favorable response to Atezolizumab therapy?","In a male patient with bladder urothelial carcinoma (BLCA), a tumor mutational burden of 10.0, and mRNA TPM expression profiling from a bladder biopsy to evaluate the tumor immune microenvironment, what is the likelihood of a favorable response to Atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/9e11ec-ar-9e11ec6.pkl. "
BLCA,6.0,0.431372549,desert,NR,"In a female patient with bladder urothelial carcinoma, where the bladder biopsy indicates specific mRNA TPM expression levels related to the tumor immune microenvironment and the tumor mutational burden is 6.0, would you expect a favorable response to atezolizumab therapy?","In a female patient with bladder urothelial carcinoma, where the bladder biopsy indicates specific mRNA TPM expression levels related to the tumor immune microenvironment and the tumor mutational burden is 6.0, would you expect a favorable response to atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/9fb814-ar-9fb814c.pkl. "
BLCA,,3.333333333,desert,NR,"I have a female patient with bladder urothelial carcinoma for whom we measured mRNA TPM expression from a bladder biopsy to evaluate the tumor immune microenvironment. The tumor mutational burden result is reported as ""nan."" Given these findings, what is the likelihood of a favorable response to Atezolizumab therapy?","I have a female patient with bladder urothelial carcinoma for whom we measured mRNA TPM expression from a bladder biopsy to evaluate the tumor immune microenvironment. The tumor mutational burden result is reported as ""nan."" Given these findings, what is the likelihood of a favorable response to Atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/a1871f-ar-a1871f4.pkl. "
BLCA,15.0,0.921568627,inflamed,NR,"I have a female patient with bladder urothelial carcinoma who underwent a bladder biopsy for mRNA TPM expression profiling to assess the tumor's immune microenvironment. With a tumor mutational burden of 15.0, would you consider Atezolizumab likely to be effective for her treatment?","I have a female patient with bladder urothelial carcinoma who underwent a bladder biopsy for mRNA TPM expression profiling to assess the tumor's immune microenvironment. With a tumor mutational burden of 15.0, would you consider Atezolizumab likely to be effective for her treatment?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/a1e62d-ar-a1e62d3.pkl. "
BLCA,8.0,1.411764706,excluded,NR,"In a male patient with bladder urothelial carcinoma whose lymph node biopsy revealed mRNA TPM expression indicative of the tumor immune microenvironment, and with a tumor mutational burden of 8.0, how likely is he to respond to atezolizumab treatment?","In a male patient with bladder urothelial carcinoma whose lymph node biopsy revealed mRNA TPM expression indicative of the tumor immune microenvironment, and with a tumor mutational burden of 8.0, how likely is he to respond to atezolizumab treatment?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/a32177-ar-a321770.pkl. "
BLCA,6.0,0.68627451,,NR,"In a patient with bladder urothelial carcinoma, where mRNA TPM expression has been assessed via bladder biopsy and the tumor mutational burden is 6.0, is Atezolizumab likely to be an effective treatment option?","In a patient with bladder urothelial carcinoma, where mRNA TPM expression has been assessed via bladder biopsy and the tumor mutational burden is 6.0, is Atezolizumab likely to be an effective treatment option?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/a424c7-ar-a424c75.pkl. "
BLCA,19.0,0.882352941,,R,"For a male patient with bladder urothelial carcinoma who has had mRNA TPM expression evaluated from a bladder biopsy to characterize the tumor immune microenvironment and exhibits a tumor mutational burden of 19.0, what is the likelihood of a favorable response to Atezolizumab therapy?","For a male patient with bladder urothelial carcinoma who has had mRNA TPM expression evaluated from a bladder biopsy to characterize the tumor immune microenvironment and exhibits a tumor mutational burden of 19.0, what is the likelihood of a favorable response to Atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/a535fc-ar-a535fcd.pkl. "
BLCA,12.0,0.725490196,,NR,"I have a male patient with bladder urothelial carcinoma whose mRNA TPM expression was measured from an alternative biopsy to evaluate the tumor immune microenvironment, and the tumor mutational burden is 12.0. Based on these parameters, can we expect a favorable response to Atezolizumab?","I have a male patient with bladder urothelial carcinoma whose mRNA TPM expression was measured from an alternative biopsy to evaluate the tumor immune microenvironment, and the tumor mutational burden is 12.0. Based on these parameters, can we expect a favorable response to Atezolizumab?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/a90d73-ar-a90d73f.pkl. "
BLCA,,1.529411765,excluded,NR,"I am evaluating a male patient with bladder urothelial carcinoma whose kidney biopsy provided mRNA TPM expression data to assess the tumor immune microenvironment, but his tumor mutational burden is reported as ""nan."" Given these findings and the consideration of Atezolizumab therapy, what can be inferred about his likelihood of responding to treatment?","I am evaluating a male patient with bladder urothelial carcinoma whose kidney biopsy provided mRNA TPM expression data to assess the tumor immune microenvironment, but his tumor mutational burden is reported as ""nan."" Given these findings and the consideration of Atezolizumab therapy, what can be inferred about his likelihood of responding to treatment?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/a913c6-ar-a913c61.pkl. "
BLCA,3.0,0.352941176,,NR,"For a male patient with bladder urothelial carcinoma, whose tumor immune microenvironment was profiled using mRNA TPM expression from a bladder biopsy and who exhibits a tumor mutational burden of 3.0, would treatment with Atezolizumab be expected to yield a favorable response?","For a male patient with bladder urothelial carcinoma, whose tumor immune microenvironment was profiled using mRNA TPM expression from a bladder biopsy and who exhibits a tumor mutational burden of 3.0, would treatment with Atezolizumab be expected to yield a favorable response?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/a9ca85-ar-a9ca853.pkl. "
BLCA,18.0,2.0,,NR,"I have a male patient with bladder urothelial carcinoma (BLCA) who has a tumor mutational burden of 18.0. mRNA TPM expression was measured from a lymph node biopsy to assess the tumor immune microenvironment. Based on these findings, how likely is he to respond to Atezolizumab therapy?","I have a male patient with bladder urothelial carcinoma (BLCA) who has a tumor mutational burden of 18.0. mRNA TPM expression was measured from a lymph node biopsy to assess the tumor immune microenvironment. Based on these findings, how likely is he to respond to Atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/aabf4a-ar-aabf4af.pkl. "
BLCA,15.0,1.725490196,excluded,R,"I have a male patient with bladder urothelial carcinoma whose mRNA TPM expression was measured from a kidney biopsy to evaluate the tumor immune microenvironment. The patient's tumor mutational burden is 15.0. Given these findings, would you expect a favorable response to Atezolizumab therapy?","I have a male patient with bladder urothelial carcinoma whose mRNA TPM expression was measured from a kidney biopsy to evaluate the tumor immune microenvironment. The patient's tumor mutational burden is 15.0. Given these findings, would you expect a favorable response to Atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/aaf505-ar-aaf505c.pkl. "
BLCA,,0.039215686,inflamed,NR,"I have a male patient with bladder urothelial carcinoma who underwent a lymph node biopsy, yielding mRNA TPM expression data for evaluation of the tumor immune microenvironment. The tumor mutational burden is reported as 'nan'. Considering initiating atezolizumab therapy, is there sufficient evidence from these factors to predict a response to the treatment?","I have a male patient with bladder urothelial carcinoma who underwent a lymph node biopsy, yielding mRNA TPM expression data for evaluation of the tumor immune microenvironment. The tumor mutational burden is reported as 'nan'. Considering initiating atezolizumab therapy, is there sufficient evidence from these factors to predict a response to the treatment?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/ab8052-ar-ab8052a.pkl. "
BLCA,,,excluded,NR,"I have a patient with bladder urothelial carcinoma whose mRNA TPM expression was measured from a bladder biopsy to assess the tumor immune microenvironment. The tumor mutational burden is not available, and I am considering treatment with atezolizumab. Given these factors, what is the likelihood that the patient will respond to this therapy?","I have a patient with bladder urothelial carcinoma whose mRNA TPM expression was measured from a bladder biopsy to assess the tumor immune microenvironment. The tumor mutational burden is not available, and I am considering treatment with atezolizumab. Given these factors, what is the likelihood that the patient will respond to this therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/abc151-ar-abc151b.pkl. "
BLCA,6.0,0.745098039,,NR,"I have a male patient with bladder urothelial carcinoma (BLCA) who underwent a kidney biopsy for mRNA TPM expression analysis of the tumor immune microenvironment. With a tumor mutational burden (TMB) of 6.0, how likely is he to respond to Atezolizumab therapy?","I have a male patient with bladder urothelial carcinoma (BLCA) who underwent a kidney biopsy for mRNA TPM expression analysis of the tumor immune microenvironment. With a tumor mutational burden (TMB) of 6.0, how likely is he to respond to Atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/ad83c9-ar-ad83c9c.pkl. "
BLCA,,,,NR,"For a female patient with bladder urothelial carcinoma, whose tumor immune microenvironment was assessed through mRNA TPM expression from a kidney biopsy and who has a reported tumor mutational burden (TMB) of ""nan,"" would Atezolizumab be an appropriate treatment option, and how likely is a positive therapeutic response?","For a female patient with bladder urothelial carcinoma, whose tumor immune microenvironment was assessed through mRNA TPM expression from a kidney biopsy and who has a reported tumor mutational burden (TMB) of ""nan,"" would Atezolizumab be an appropriate treatment option, and how likely is a positive therapeutic response?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/ae0262-ar-ae02629.pkl. "
BLCA,,,,NR,"I have a male patient with bladder urothelial carcinoma who underwent a ureter biopsy for mRNA TPM expression analysis to evaluate the tumor immune microenvironment, but his tumor mutational burden is unavailable. Based on these findings, how likely is he to respond to Atezolizumab therapy?","I have a male patient with bladder urothelial carcinoma who underwent a ureter biopsy for mRNA TPM expression analysis to evaluate the tumor immune microenvironment, but his tumor mutational burden is unavailable. Based on these findings, how likely is he to respond to Atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/ae1690-ar-ae16904.pkl. "
BLCA,,,,NR,"I have a female patient with bladder urothelial carcinoma whose tumor immune microenvironment was evaluated via mRNA TPM expression from a bladder biopsy, although her tumor mutational burden is not available. Given these data, what is the expected likelihood of her responding to Atezolizumab therapy?","I have a female patient with bladder urothelial carcinoma whose tumor immune microenvironment was evaluated via mRNA TPM expression from a bladder biopsy, although her tumor mutational burden is not available. Given these data, what is the expected likelihood of her responding to Atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/ae4da2-ar-ae4da27.pkl. "
BLCA,4.0,,excluded,R,"For a male patient with bladder urothelial carcinoma whose mRNA TPM expression was evaluated from a ureter biopsy to assess the tumor immune microenvironment and who has a tumor mutational burden of 4.0, would you expect a favorable response to treatment with atezolizumab?","For a male patient with bladder urothelial carcinoma whose mRNA TPM expression was evaluated from a ureter biopsy to assess the tumor immune microenvironment and who has a tumor mutational burden of 4.0, would you expect a favorable response to treatment with atezolizumab?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/aec738-ar-aec7380.pkl. "
BLCA,14.0,2.196078431,inflamed,NR,"In a patient with bladder urothelial carcinoma who has a tumor mutational burden of 14.0 and mRNA TPM expression data from a bladder biopsy indicating the tumor immune microenvironment, would treatment with Atezolizumab be expected to be effective?","In a patient with bladder urothelial carcinoma who has a tumor mutational burden of 14.0 and mRNA TPM expression data from a bladder biopsy indicating the tumor immune microenvironment, would treatment with Atezolizumab be expected to be effective?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/af42c1-ar-af42c15.pkl. "
BLCA,7.0,0.352941176,,NR,"In a male patient with bladder urothelial carcinoma and a tumor mutational burden of 7.0, whose tumor immune microenvironment was assessed via mRNA TPM expression from a lung biopsy, how likely is he to benefit from Atezolizumab therapy?","In a male patient with bladder urothelial carcinoma and a tumor mutational burden of 7.0, whose tumor immune microenvironment was assessed via mRNA TPM expression from a lung biopsy, how likely is he to benefit from Atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/b0a83e-ar-b0a83e5.pkl. "
BLCA,3.0,0.843137255,inflamed,NR,"I have a female patient with bladder urothelial carcinoma whose mRNA TPM expression was measured from a lung biopsy to evaluate the tumor immune microenvironment, and her tumor mutational burden is 3.0. Considering these factors, is she likely to respond to Atezolizumab therapy?","I have a female patient with bladder urothelial carcinoma whose mRNA TPM expression was measured from a lung biopsy to evaluate the tumor immune microenvironment, and her tumor mutational burden is 3.0. Considering these factors, is she likely to respond to Atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/b0d11d-ar-b0d11db.pkl. "
BLCA,11.0,1.509803922,,R,"I have a patient with bladder urothelial carcinoma whose bladder biopsy showed mRNA TPM expression profiling of the tumor immune microenvironment and a tumor mutational burden of 11.0. Based on these findings, would you expect the patient to respond favorably to atezolizumab therapy?","I have a patient with bladder urothelial carcinoma whose bladder biopsy showed mRNA TPM expression profiling of the tumor immune microenvironment and a tumor mutational burden of 11.0. Based on these findings, would you expect the patient to respond favorably to atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/b15ac6-ar-b15ac6e.pkl. "
BLCA,4.0,,excluded,NR,"In a female patient with bladder urothelial carcinoma who has undergone mRNA TPM expression profiling from a bladder biopsy and exhibits a tumor mutational burden of 4.0, how likely is she to respond to Atezolizumab therapy?","In a female patient with bladder urothelial carcinoma who has undergone mRNA TPM expression profiling from a bladder biopsy and exhibits a tumor mutational burden of 4.0, how likely is she to respond to Atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/b15ad0-ar-b15ad09.pkl. "
BLCA,,,,NR,"In a female patient with bladder urothelial carcinoma, mRNA TPM expression analysis from a biopsy has been used to assess the tumor immune microenvironment, and the reported tumor mutational burden is not available (nan). Given these results, is a response to Atezolizumab therapy likely?","In a female patient with bladder urothelial carcinoma, mRNA TPM expression analysis from a biopsy has been used to assess the tumor immune microenvironment, and the reported tumor mutational burden is not available (nan). Given these results, is a response to Atezolizumab therapy likely?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/b2e4a0-ar-b2e4a08.pkl. "
BLCA,,0.862745098,desert,R,"We have a male patient with bladder urothelial carcinoma whose bladder biopsy provided mRNA TPM expression data to evaluate the tumor immune microenvironment. His tumor mutational burden is reported as ""nan."" Given this molecular profile, how likely is he to respond to atezolizumab therapy?","We have a male patient with bladder urothelial carcinoma whose bladder biopsy provided mRNA TPM expression data to evaluate the tumor immune microenvironment. His tumor mutational burden is reported as ""nan."" Given this molecular profile, how likely is he to respond to atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/b2f1d0-ar-b2f1d0e.pkl. "
BLCA,18.0,,desert,R,"In a male patient with bladder urothelial carcinoma who was evaluated with mRNA TPM expression analysis from a tumor biopsy and has a tumor mutational burden of 18.0, is there a justified expectation of clinical benefit from treatment with Atezolizumab?","In a male patient with bladder urothelial carcinoma who was evaluated with mRNA TPM expression analysis from a tumor biopsy and has a tumor mutational burden of 18.0, is there a justified expectation of clinical benefit from treatment with Atezolizumab?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/b3c022-ar-b3c0229.pkl. "
BLCA,19.0,,excluded,R,"For a male patient with bladder urothelial carcinoma who has a tumor mutational burden of 19 and mRNA TPM expression data from a bladder biopsy that characterizes the immune microenvironment, does this profile suggest a favorable response to Atezolizumab therapy?","For a male patient with bladder urothelial carcinoma who has a tumor mutational burden of 19 and mRNA TPM expression data from a bladder biopsy that characterizes the immune microenvironment, does this profile suggest a favorable response to Atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/b419a8-ar-b419a8f.pkl. "
BLCA,35.0,,excluded,R,"I have a patient with bladder urothelial carcinoma whose mRNA TPM expression was assessed from a bladder biopsy, and the tumor mutational burden is 35.0. Given this profile, what is the likelihood that the patient will respond favorably to Atezolizumab therapy?","I have a patient with bladder urothelial carcinoma whose mRNA TPM expression was assessed from a bladder biopsy, and the tumor mutational burden is 35.0. Given this profile, what is the likelihood that the patient will respond favorably to Atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/b470eb-ar-b470eb8.pkl. "
BLCA,5.0,,inflamed,NR,"I have a male patient with bladder urothelial carcinoma whose tumor immune microenvironment was characterized using mRNA TPM expression from a kidney biopsy, and his tumor mutational burden is 5.0. Based on these findings, how likely is he to respond to atezolizumab therapy?","I have a male patient with bladder urothelial carcinoma whose tumor immune microenvironment was characterized using mRNA TPM expression from a kidney biopsy, and his tumor mutational burden is 5.0. Based on these findings, how likely is he to respond to atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/b4c7a0-ar-b4c7a00.pkl. "
BLCA,5.0,0.333333333,desert,NR,"In a patient with bladder urothelial carcinoma whose bladder biopsy shows specific mRNA TPM expression levels and a tumor mutational burden of 5.0, is there evidence to suggest that treatment with atezolizumab would be effective based on these molecular characteristics?","In a patient with bladder urothelial carcinoma whose bladder biopsy shows specific mRNA TPM expression levels and a tumor mutational burden of 5.0, is there evidence to suggest that treatment with atezolizumab would be effective based on these molecular characteristics?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/b8070b-ar-b8070b7.pkl. "
BLCA,16.0,3.764705882,inflamed,NR,"I have a male patient with bladder urothelial carcinoma whose bladder biopsy revealed an mRNA TPM expression profile assessing the tumor immune microenvironment and a tumor mutational burden of 16.0. Based on these findings, is he likely to respond favorably to Atezolizumab therapy?","I have a male patient with bladder urothelial carcinoma whose bladder biopsy revealed an mRNA TPM expression profile assessing the tumor immune microenvironment and a tumor mutational burden of 16.0. Based on these findings, is he likely to respond favorably to Atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/b8101c-ar-b8101c5.pkl. "
BLCA,8.0,0.882352941,excluded,NR,"For a male patient with bladder urothelial carcinoma, whose biopsy reveals mRNA TPM expression profiling of the tumor immune microenvironment and a tumor mutational burden of 8.0, how likely is it that the patient will respond to treatment with atezolizumab?","For a male patient with bladder urothelial carcinoma, whose biopsy reveals mRNA TPM expression profiling of the tumor immune microenvironment and a tumor mutational burden of 8.0, how likely is it that the patient will respond to treatment with atezolizumab?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/b963dd-ar-b963dda.pkl. "
BLCA,5.0,0.901960784,inflamed,NR,"For a male patient with bladder urothelial carcinoma, whose tumor immune microenvironment was assessed via mRNA TPM expression from a bladder biopsy and who has a tumor mutational burden of 5.0, how likely is he to respond to treatment with atezolizumab?","For a male patient with bladder urothelial carcinoma, whose tumor immune microenvironment was assessed via mRNA TPM expression from a bladder biopsy and who has a tumor mutational burden of 5.0, how likely is he to respond to treatment with atezolizumab?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/ba1a34-ar-ba1a34b.pkl. "
BLCA,5.0,,excluded,NR,"I have a female patient with bladder urothelial carcinoma (BLCA) whose tumor immune microenvironment was characterized via mRNA TPM expression from a kidney biopsy, and her tumor mutational burden is 5.0. Given these factors, is treatment with atezolizumab likely to be effective?","I have a female patient with bladder urothelial carcinoma (BLCA) whose tumor immune microenvironment was characterized via mRNA TPM expression from a kidney biopsy, and her tumor mutational burden is 5.0. Given these factors, is treatment with atezolizumab likely to be effective?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/ba7176-ar-ba7176a.pkl. "
BLCA,7.0,0.745098039,desert,NR,"I have a female patient with bladder urothelial carcinoma. Biopsy analysis including mRNA TPM expression profiling to assess the tumor immune microenvironment shows a tumor mutational burden of 7.0. Based on these findings, would she be likely to respond to atezolizumab therapy?","I have a female patient with bladder urothelial carcinoma. Biopsy analysis including mRNA TPM expression profiling to assess the tumor immune microenvironment shows a tumor mutational burden of 7.0. Based on these findings, would she be likely to respond to atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/bc8dc3-ar-bc8dc3a.pkl. "
BLCA,,,excluded,NR,"I have a male patient with bladder urothelial carcinoma (BLCA) whose mRNA TPM expression profile was obtained from a bladder biopsy to evaluate the tumor immune microenvironment. The tumor mutational burden (TMB) value is reported as ""nan."" Given these findings, how likely is it that the patient will respond to Atezolizumab therapy?","I have a male patient with bladder urothelial carcinoma (BLCA) whose mRNA TPM expression profile was obtained from a bladder biopsy to evaluate the tumor immune microenvironment. The tumor mutational burden (TMB) value is reported as ""nan."" Given these findings, how likely is it that the patient will respond to Atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/bcb07b-ar-bcb07ba.pkl. "
BLCA,9.0,,desert,NR,"I have a male patient with bladder urothelial carcinoma whose bladder biopsy showed specific mRNA TPM expression in the tumor immune microenvironment and a tumor mutational burden of 9.0 mutations per megabase. Based on these findings, how predictive is this profile of a favorable response to atezolizumab therapy?","I have a male patient with bladder urothelial carcinoma whose bladder biopsy showed specific mRNA TPM expression in the tumor immune microenvironment and a tumor mutational burden of 9.0 mutations per megabase. Based on these findings, how predictive is this profile of a favorable response to atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/bcbc79-ar-bcbc795.pkl. "
BLCA,20.0,1.254901961,inflamed,NR,"In a female patient with bladder urothelial carcinoma, whose bladder biopsy revealed mRNA TPM expression data indicative of the tumor immune microenvironment and a tumor mutational burden of 20 mutations per megabase, would the profile suggest a favorable response to Atezolizumab therapy?","In a female patient with bladder urothelial carcinoma, whose bladder biopsy revealed mRNA TPM expression data indicative of the tumor immune microenvironment and a tumor mutational burden of 20 mutations per megabase, would the profile suggest a favorable response to Atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/bda79f-ar-bda79f9.pkl. "
BLCA,10.0,0.784313725,excluded,NR,"In a female patient with bladder urothelial carcinoma who has a tumor mutational burden of 10.0 and mRNA TPM expression data from a lymph node biopsy assessing the tumor immune microenvironment, would treatment with Atezolizumab be expected to yield a favorable response?","In a female patient with bladder urothelial carcinoma who has a tumor mutational burden of 10.0 and mRNA TPM expression data from a lymph node biopsy assessing the tumor immune microenvironment, would treatment with Atezolizumab be expected to yield a favorable response?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/be83ea-ar-be83eae.pkl. "
BLCA,35.0,3.745098039,excluded,R,"I have a male patient with bladder urothelial carcinoma whose tumor analysis shows a high mutational burden (35.0) along with mRNA TPM expression data from a bladder biopsy assessing the immune microenvironment. Based on these factors, how likely is the patient to respond to atezolizumab therapy?","I have a male patient with bladder urothelial carcinoma whose tumor analysis shows a high mutational burden (35.0) along with mRNA TPM expression data from a bladder biopsy assessing the immune microenvironment. Based on these factors, how likely is the patient to respond to atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/bf1a3a-ar-bf1a3ae.pkl. "
BLCA,6.0,1.450980392,excluded,NR,"I have a female patient with bladder urothelial carcinoma whose biopsy revealed an mRNA TPM expression profile to assess the tumor immune microenvironment and a tumor mutational burden of 6.0. Based on these factors, how likely is she to respond to Atezolizumab therapy?","I have a female patient with bladder urothelial carcinoma whose biopsy revealed an mRNA TPM expression profile to assess the tumor immune microenvironment and a tumor mutational burden of 6.0. Based on these factors, how likely is she to respond to Atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/bfdffb-ar-bfdffb9.pkl. "
BLCA,3.0,0.294117647,desert,NR,"In a female patient with bladder urothelial carcinoma who has a tumor mutational burden of 3.0 and mRNA TPM expression data from a bladder biopsy assessing the immune microenvironment, would treatment with atezolizumab be expected to be effective?","In a female patient with bladder urothelial carcinoma who has a tumor mutational burden of 3.0 and mRNA TPM expression data from a bladder biopsy assessing the immune microenvironment, would treatment with atezolizumab be expected to be effective?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/c0d625-ar-c0d625a.pkl. "
BLCA,5.0,1.176470588,desert,NR,"In a male patient with bladder urothelial carcinoma, how predictive is a tumor mutational burden of 5.0, along with mRNA TPM expression profiling of the tumor immune microenvironment from a bladder biopsy, of a favorable response to atezolizumab?","In a male patient with bladder urothelial carcinoma, how predictive is a tumor mutational burden of 5.0, along with mRNA TPM expression profiling of the tumor immune microenvironment from a bladder biopsy, of a favorable response to atezolizumab?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/c0da5d-ar-c0da5d4.pkl. "
BLCA,5.0,0.960784314,desert,NR,"In a male patient with bladder urothelial carcinoma, we observed mRNA TPM expression from a nanobiopsy assessing the tumor immune microenvironment, and the tumor mutational burden (TMB) is 5.0. Considering these factors, would this patient be a likely candidate for a positive response to atezolizumab therapy?","In a male patient with bladder urothelial carcinoma, we observed mRNA TPM expression from a nanobiopsy assessing the tumor immune microenvironment, and the tumor mutational burden (TMB) is 5.0. Considering these factors, would this patient be a likely candidate for a positive response to atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/c0ef41-ar-c0ef41a.pkl. "
BLCA,5.0,1.098039216,excluded,R,"I have a male patient diagnosed with bladder urothelial carcinoma. His bladder biopsy shows mRNA TPM expression data reflecting the tumor immune microenvironment, and his tumor mutational burden is 5.0. Given these findings, what is the likelihood that he will respond to Atezolizumab therapy?","I have a male patient diagnosed with bladder urothelial carcinoma. His bladder biopsy shows mRNA TPM expression data reflecting the tumor immune microenvironment, and his tumor mutational burden is 5.0. Given these findings, what is the likelihood that he will respond to Atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/c1251c-ar-c1251c7.pkl. "
BLCA,5.0,1.411764706,excluded,R,"I have a patient with bladder urothelial carcinoma (BLCA) whose mRNA TPM expression was assessed from a kidney biopsy to evaluate the tumor immune microenvironment. The patient’s tumor mutational burden (TMB) is 5.0. Based on these findings, can we expect a favorable response to Atezolizumab therapy?","I have a patient with bladder urothelial carcinoma (BLCA) whose mRNA TPM expression was assessed from a kidney biopsy to evaluate the tumor immune microenvironment. The patient’s tumor mutational burden (TMB) is 5.0. Based on these findings, can we expect a favorable response to Atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/c1b27b-ar-c1b27bc.pkl. "
BLCA,,,excluded,R,For a male patient with bladder urothelial carcinoma who has undergone a bladder biopsy with mRNA TPM analysis for tumor immune microenvironment assessment—and with a tumor mutational burden value reported as “nan”—how likely is he to benefit from Atezolizumab therapy?,For a male patient with bladder urothelial carcinoma who has undergone a bladder biopsy with mRNA TPM analysis for tumor immune microenvironment assessment—and with a tumor mutational burden value reported as “nan”—how likely is he to benefit from Atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/c2a182-ar-c2a1820.pkl. 
BLCA,3.0,0.196078431,desert,NR,"I have a male patient with bladder urothelial carcinoma whose mRNA TPM expression profile was obtained from a bladder biopsy to evaluate the tumor immune microenvironment. The tumor has a mutational burden of 3.0. Based on these factors, how likely is it that this patient will respond to atezolizumab therapy?","I have a male patient with bladder urothelial carcinoma whose mRNA TPM expression profile was obtained from a bladder biopsy to evaluate the tumor immune microenvironment. The tumor has a mutational burden of 3.0. Based on these factors, how likely is it that this patient will respond to atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/c57ead-ar-c57eadb.pkl. "
BLCA,10.0,,desert,NR,"For a bladder urothelial carcinoma patient with a tumor mutational burden of 10.0 and mRNA TPM expression evaluated from a ureter biopsy to assess the tumor immune microenvironment, is there evidence to suggest that treatment with Atezolizumab would be effective?","For a bladder urothelial carcinoma patient with a tumor mutational burden of 10.0 and mRNA TPM expression evaluated from a ureter biopsy to assess the tumor immune microenvironment, is there evidence to suggest that treatment with Atezolizumab would be effective?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/c69253-ar-c692536.pkl. "
BLCA,3.0,0.450980392,excluded,NR,"I have a male patient with bladder urothelial carcinoma who underwent lymph node biopsy for mRNA TPM expression profiling to assess the tumor immune microenvironment. The tumor shows a TMB of 3.0. Given this information, how likely is the patient to respond to Atezolizumab therapy?","I have a male patient with bladder urothelial carcinoma who underwent lymph node biopsy for mRNA TPM expression profiling to assess the tumor immune microenvironment. The tumor shows a TMB of 3.0. Given this information, how likely is the patient to respond to Atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/c6eff0-ar-c6eff05.pkl. "
BLCA,3.0,0.607843137,inflamed,R,"I have a patient with bladder urothelial carcinoma whose bladder biopsy shows mRNA TPM expression for assessment of the tumor immune microenvironment, and the tumor mutational burden is 3.0. Given these findings, is Atezolizumab likely to produce a clinical response?","I have a patient with bladder urothelial carcinoma whose bladder biopsy shows mRNA TPM expression for assessment of the tumor immune microenvironment, and the tumor mutational burden is 3.0. Given these findings, is Atezolizumab likely to produce a clinical response?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/c919ae-ar-c919aeb.pkl. "
BLCA,11.0,1.352941176,inflamed,NR,"I have a female patient with bladder urothelial carcinoma whose tumor microenvironment was assessed using mRNA TPM expression from a lung biopsy, and her tumor mutational burden is 11.0. Based on these findings, is she likely to respond favorably to Atezolizumab?","I have a female patient with bladder urothelial carcinoma whose tumor microenvironment was assessed using mRNA TPM expression from a lung biopsy, and her tumor mutational burden is 11.0. Based on these findings, is she likely to respond favorably to Atezolizumab?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/cabb6d-ar-cabb6d5.pkl. "
BLCA,,0.843137255,desert,NR,"A patient with bladder urothelial carcinoma has had their lymph node biopsy analyzed for mRNA TPM expression to evaluate the tumor immune microenvironment, but the tumor mutational burden data is unavailable. Given these factors, how likely is this patient to respond to atezolizumab therapy?","A patient with bladder urothelial carcinoma has had their lymph node biopsy analyzed for mRNA TPM expression to evaluate the tumor immune microenvironment, but the tumor mutational burden data is unavailable. Given these factors, how likely is this patient to respond to atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/cb132b-ar-cb132b0.pkl. "
BLCA,,,,NR,"I have a male patient with bladder urothelial carcinoma who underwent a liver biopsy for mRNA TPM expression analysis to evaluate his tumor immune microenvironment. However, the tumor mutational burden (TMB) is reported as nan. Based on these findings, how likely is it that he will respond to Atezolizumab therapy?","I have a male patient with bladder urothelial carcinoma who underwent a liver biopsy for mRNA TPM expression analysis to evaluate his tumor immune microenvironment. However, the tumor mutational burden (TMB) is reported as nan. Based on these findings, how likely is it that he will respond to Atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/cc4675-ar-cc4675f.pkl. "
BLCA,26.0,4.960784314,inflamed,R,"A female patient with bladder urothelial carcinoma has undergone mRNA TPM expression profiling from a ureter biopsy to assess her tumor's immune microenvironment, and her tumor mutational burden is 26.0. Based on these findings, is she likely to respond to Atezolizumab therapy?","A female patient with bladder urothelial carcinoma has undergone mRNA TPM expression profiling from a ureter biopsy to assess her tumor's immune microenvironment, and her tumor mutational burden is 26.0. Based on these findings, is she likely to respond to Atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/cc7a42-ar-cc7a42d.pkl. "
BLCA,14.0,0.843137255,inflamed,NR,"For a male patient with bladder urothelial carcinoma who has undergone biopsy with mRNA TPM expression analysis of the tumor immune microenvironment, and who has a tumor mutational burden of 14.0 mutations per megabase, what is the predicted likelihood of response to atezolizumab therapy?","For a male patient with bladder urothelial carcinoma who has undergone biopsy with mRNA TPM expression analysis of the tumor immune microenvironment, and who has a tumor mutational burden of 14.0 mutations per megabase, what is the predicted likelihood of response to atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/ce39dd-ar-ce39dd7.pkl. "
BLCA,,,excluded,NR,"I have a male patient with bladder urothelial carcinoma whose mRNA TPM expression was measured from a lung biopsy to evaluate the tumor immune microenvironment, and his tumor mutational burden (TMB) is currently undetermined. Based on these factors, would you expect him to respond to Atezolizumab?","I have a male patient with bladder urothelial carcinoma whose mRNA TPM expression was measured from a lung biopsy to evaluate the tumor immune microenvironment, and his tumor mutational burden (TMB) is currently undetermined. Based on these factors, would you expect him to respond to Atezolizumab?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/cf018f-ar-cf018fe.pkl. "
BLCA,4.0,0.764705882,desert,R,"I have a female patient with bladder urothelial carcinoma whose mRNA TPM expression has been assessed via a ureter biopsy to evaluate the tumor immune microenvironment. She has a tumor mutational burden of 4.0. Based on these findings, would Atezolizumab be a suitable treatment option for her?","I have a female patient with bladder urothelial carcinoma whose mRNA TPM expression has been assessed via a ureter biopsy to evaluate the tumor immune microenvironment. She has a tumor mutational burden of 4.0. Based on these findings, would Atezolizumab be a suitable treatment option for her?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/d02712-ar-d027124.pkl. "
BLCA,3.0,0.607843137,excluded,NR,"In a male patient with bladder urothelial carcinoma, our biopsy mRNA expression analysis via TPM was used to evaluate the tumor immune microenvironment, and his tumor mutational burden is 3.0. Based on these findings, how likely is he to respond to Atezolizumab?","In a male patient with bladder urothelial carcinoma, our biopsy mRNA expression analysis via TPM was used to evaluate the tumor immune microenvironment, and his tumor mutational burden is 3.0. Based on these findings, how likely is he to respond to Atezolizumab?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/d135d5-ar-d135d58.pkl. "
BLCA,22.0,,,NR,"I have a male patient with bladder urothelial carcinoma. The patient's mRNA TPM expression from a bladder biopsy has been analyzed to characterize the tumor immune microenvironment, and his tumor mutational burden is 22 mutations per megabase. Given these findings, is he likely to respond to treatment with atezolizumab?","I have a male patient with bladder urothelial carcinoma. The patient's mRNA TPM expression from a bladder biopsy has been analyzed to characterize the tumor immune microenvironment, and his tumor mutational burden is 22 mutations per megabase. Given these findings, is he likely to respond to treatment with atezolizumab?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/d1bd63-ar-d1bd637.pkl. "
BLCA,,,,NR,"I have a male patient with bladder urothelial carcinoma whose mRNA TPM expression levels were measured from a bladder biopsy to evaluate the tumor immune microenvironment. The tumor mutational burden (TMB) is not available. Given these parameters, do you think the patient is likely to respond to atezolizumab therapy?","I have a male patient with bladder urothelial carcinoma whose mRNA TPM expression levels were measured from a bladder biopsy to evaluate the tumor immune microenvironment. The tumor mutational burden (TMB) is not available. Given these parameters, do you think the patient is likely to respond to atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/d215b5-ar-d215b50.pkl. "
BLCA,3.0,0.490196078,desert,NR,"I have a female patient with bladder urothelial carcinoma, and her lymph node biopsy showed specific mRNA TPM expression levels indicative of her tumor’s immune microenvironment. With a tumor mutational burden (TMB) of 3.0, how likely is she to respond to treatment with Atezolizumab?","I have a female patient with bladder urothelial carcinoma, and her lymph node biopsy showed specific mRNA TPM expression levels indicative of her tumor’s immune microenvironment. With a tumor mutational burden (TMB) of 3.0, how likely is she to respond to treatment with Atezolizumab?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/d2492b-ar-d2492b2.pkl. "
BLCA,62.0,10.01960784,excluded,R,"I have a male patient with bladder urothelial carcinoma whose tumor mRNA TPM expression has been assessed via kidney biopsy, and the tumor mutational burden is 62. Considering these findings, how likely is the patient to respond to Atezolizumab therapy?","I have a male patient with bladder urothelial carcinoma whose tumor mRNA TPM expression has been assessed via kidney biopsy, and the tumor mutational burden is 62. Considering these findings, how likely is the patient to respond to Atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/d35318-ar-d353181.pkl. "
BLCA,14.0,0.784313725,excluded,R,"For a male patient with bladder urothelial carcinoma, whose tumor immune microenvironment was characterized by mRNA TPM expression from a separate biopsy and who has a tumor mutational burden of 14.0, would Atezolizumab be likely to elicit a favorable response?","For a male patient with bladder urothelial carcinoma, whose tumor immune microenvironment was characterized by mRNA TPM expression from a separate biopsy and who has a tumor mutational burden of 14.0, would Atezolizumab be likely to elicit a favorable response?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/d36012-ar-d360128.pkl. "
BLCA,7.0,1.568627451,excluded,R,"I have a male patient with bladder urothelial carcinoma. A lymph node biopsy revealed specific mRNA TPM expression levels, and his tumor mutational burden is 7.0. Based on these findings, how likely is he to respond to atezolizumab therapy?","I have a male patient with bladder urothelial carcinoma. A lymph node biopsy revealed specific mRNA TPM expression levels, and his tumor mutational burden is 7.0. Based on these findings, how likely is he to respond to atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/d3bd67-ar-d3bd679.pkl. "
BLCA,15.0,1.882352941,inflamed,R,"In a male patient with bladder urothelial carcinoma, whose tumor biopsy shows specific mRNA TPM expression levels and a tumor mutational burden of 15.0 mutations per megabase, is it reasonable to expect a beneficial response to atezolizumab therapy?","In a male patient with bladder urothelial carcinoma, whose tumor biopsy shows specific mRNA TPM expression levels and a tumor mutational burden of 15.0 mutations per megabase, is it reasonable to expect a beneficial response to atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/d43f89-ar-d43f893.pkl. "
BLCA,5.0,0.529411765,excluded,NR,"In a middle-aged patient with bladder urothelial carcinoma who underwent kidney biopsy for mRNA TPM expression analysis of the tumor immune microenvironment and exhibits a tumor mutational burden of 5.0, what is the likelihood of a favorable response to Atezolizumab therapy?","In a middle-aged patient with bladder urothelial carcinoma who underwent kidney biopsy for mRNA TPM expression analysis of the tumor immune microenvironment and exhibits a tumor mutational burden of 5.0, what is the likelihood of a favorable response to Atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/d4c083-ar-d4c0837.pkl. "
BLCA,,0.196078431,inflamed,NR,"I have a male patient with bladder urothelial carcinoma. His mRNA TPM expression from a bladder biopsy has been evaluated to assess the tumor immune microenvironment, but his tumor mutational burden data is unavailable (nan). Based on these findings, how likely is he to respond to Atezolizumab therapy?","I have a male patient with bladder urothelial carcinoma. His mRNA TPM expression from a bladder biopsy has been evaluated to assess the tumor immune microenvironment, but his tumor mutational burden data is unavailable (nan). Based on these findings, how likely is he to respond to Atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/d636e3-ar-d636e34.pkl. "
BLCA,,,excluded,NR,"I have a female patient with bladder urothelial carcinoma. mRNA TPM expression was evaluated from a ureter biopsy to assess the tumor’s immune microenvironment, but the tumor mutational burden is currently indeterminate. Considering these factors, how likely is she to respond to Atezolizumab therapy?","I have a female patient with bladder urothelial carcinoma. mRNA TPM expression was evaluated from a ureter biopsy to assess the tumor’s immune microenvironment, but the tumor mutational burden is currently indeterminate. Considering these factors, how likely is she to respond to Atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/d697ba-ar-d697ba7.pkl. "
BLCA,24.0,,inflamed,R,"I have a male patient with bladder urothelial carcinoma whose tumor microenvironment was characterized using mRNA TPM expression from a bladder biopsy, and his tumor mutational burden is 24.0. Based on these findings, is he likely to respond to atezolizumab therapy?","I have a male patient with bladder urothelial carcinoma whose tumor microenvironment was characterized using mRNA TPM expression from a bladder biopsy, and his tumor mutational burden is 24.0. Based on these findings, is he likely to respond to atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/d7d57e-ar-d7d57ee.pkl. "
BLCA,,1.411764706,desert,NR,"I have a male patient with bladder urothelial carcinoma. mRNA TPM expression was measured from a bladder biopsy to evaluate the tumor immune microenvironment, but the tumor mutational burden (TMB) value is not available. Given these factors, what is the likelihood that the patient will respond to Atezolizumab therapy?","I have a male patient with bladder urothelial carcinoma. mRNA TPM expression was measured from a bladder biopsy to evaluate the tumor immune microenvironment, but the tumor mutational burden (TMB) value is not available. Given these factors, what is the likelihood that the patient will respond to Atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/d86389-ar-d86389d.pkl. "
BLCA,8.0,0.725490196,desert,NR,"For a male patient with bladder urothelial carcinoma who underwent ureter biopsy with mRNA TPM expression analysis to assess the tumor immune microenvironment, and with a tumor mutational burden of 8.0, what is the likelihood of a favorable response to atezolizumab therapy?","For a male patient with bladder urothelial carcinoma who underwent ureter biopsy with mRNA TPM expression analysis to assess the tumor immune microenvironment, and with a tumor mutational burden of 8.0, what is the likelihood of a favorable response to atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/d98bac-ar-d98bac0.pkl. "
BLCA,4.0,0.274509804,,NR,"For a male patient with bladder urothelial carcinoma who has a tumor mutational burden of 4.0 and mRNA TPM expression data obtained from a kidney biopsy to evaluate the tumor immune microenvironment, how likely is he to respond to Atezolizumab therapy?","For a male patient with bladder urothelial carcinoma who has a tumor mutational burden of 4.0 and mRNA TPM expression data obtained from a kidney biopsy to evaluate the tumor immune microenvironment, how likely is he to respond to Atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/da4d89-ar-da4d892.pkl. "
BLCA,14.0,2.921568627,excluded,NR,"For a male patient with bladder urothelial carcinoma, whose tumor mRNA TPM expression profile was obtained from a bladder biopsy to evaluate the immune microenvironment and who has a tumor mutational burden of 14.0, would treatment with Atezolizumab likely provide clinical benefit?","For a male patient with bladder urothelial carcinoma, whose tumor mRNA TPM expression profile was obtained from a bladder biopsy to evaluate the immune microenvironment and who has a tumor mutational burden of 14.0, would treatment with Atezolizumab likely provide clinical benefit?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/dab9ca-ar-dab9ca8.pkl. "
BLCA,5.0,0.666666667,excluded,NR,"For a male patient with bladder urothelial carcinoma, where mRNA TPM expression from a bladder biopsy was analyzed to evaluate the tumor immune microenvironment and the tumor mutational burden is 5.0, would these findings be indicative of a favorable response to atezolizumab therapy?","For a male patient with bladder urothelial carcinoma, where mRNA TPM expression from a bladder biopsy was analyzed to evaluate the tumor immune microenvironment and the tumor mutational burden is 5.0, would these findings be indicative of a favorable response to atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/dad5c2-ar-dad5c29.pkl. "
BLCA,10.0,0.509803922,excluded,NR,"In a male patient with bladder urothelial carcinoma, mRNA expression profiling from a bladder biopsy has been performed to evaluate the tumor immune microenvironment, and the tumor mutational burden is 10.0. How predictive is this profile, combined with the TMB value, for a favorable response to Atezolizumab therapy?","In a male patient with bladder urothelial carcinoma, mRNA expression profiling from a bladder biopsy has been performed to evaluate the tumor immune microenvironment, and the tumor mutational burden is 10.0. How predictive is this profile, combined with the TMB value, for a favorable response to Atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/db3f50-ar-db3f50c.pkl. "
BLCA,,1.431372549,excluded,NR,"I have a male patient with bladder urothelial carcinoma whose tumor immune microenvironment was evaluated using mRNA TPM expression from a kidney biopsy. With an indeterminate tumor mutational burden (reported as “nan”), how should I interpret his likelihood of responding to Atezolizumab therapy?","I have a male patient with bladder urothelial carcinoma whose tumor immune microenvironment was evaluated using mRNA TPM expression from a kidney biopsy. With an indeterminate tumor mutational burden (reported as “nan”), how should I interpret his likelihood of responding to Atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/dcae54-ar-dcae54f.pkl. "
BLCA,,,,NR,"A male patient with bladder urothelial carcinoma had mRNA TPM expression analyzed from a lymph node biopsy to evaluate his tumor immune microenvironment, and his tumor mutational burden was reported as “nan.” Based on these findings, what is the likelihood that he will respond to Atezolizumab therapy?","A male patient with bladder urothelial carcinoma had mRNA TPM expression analyzed from a lymph node biopsy to evaluate his tumor immune microenvironment, and his tumor mutational burden was reported as “nan.” Based on these findings, what is the likelihood that he will respond to Atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/dee101-ar-dee1011.pkl. "
BLCA,19.0,3.235294118,inflamed,NR,"In a patient with bladder urothelial carcinoma whose bladder biopsy shows an mRNA TPM expression profile and a tumor mutational burden of 19.0, would Atezolizumab be expected to elicit a favorable therapeutic response?","In a patient with bladder urothelial carcinoma whose bladder biopsy shows an mRNA TPM expression profile and a tumor mutational burden of 19.0, would Atezolizumab be expected to elicit a favorable therapeutic response?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/df3e42-ar-df3e42c.pkl. "
BLCA,5.0,0.549019608,desert,NR,"Given a female patient with bladder urothelial carcinoma who has a tumor mutational burden of 5.0 and mRNA TPM expression data obtained via ureter biopsy to evaluate the tumor immune microenvironment, would she likely benefit from treatment with Atezolizumab?","Given a female patient with bladder urothelial carcinoma who has a tumor mutational burden of 5.0 and mRNA TPM expression data obtained via ureter biopsy to evaluate the tumor immune microenvironment, would she likely benefit from treatment with Atezolizumab?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/e07c45-ar-e07c456.pkl. "
BLCA,2.0,,excluded,NR,"I have a female patient with bladder urothelial carcinoma who underwent a bladder biopsy, and mRNA TPM expression was measured to evaluate the tumor immune microenvironment. Her tumor mutational burden is 2.0. Based on these parameters, is the patient likely to respond to atezolizumab therapy?","I have a female patient with bladder urothelial carcinoma who underwent a bladder biopsy, and mRNA TPM expression was measured to evaluate the tumor immune microenvironment. Her tumor mutational burden is 2.0. Based on these parameters, is the patient likely to respond to atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/e0c49e-ar-e0c49ea.pkl. "
BLCA,14.0,2.274509804,inflamed,R,"I have a male patient with bladder urothelial carcinoma (BLCA) whose mRNA TPM expression was analyzed from a bladder biopsy to evaluate the tumor immune microenvironment. The tumor mutational burden (TMB) is 14.0. Based on these findings, how likely is this patient to respond to Atezolizumab therapy?","I have a male patient with bladder urothelial carcinoma (BLCA) whose mRNA TPM expression was analyzed from a bladder biopsy to evaluate the tumor immune microenvironment. The tumor mutational burden (TMB) is 14.0. Based on these findings, how likely is this patient to respond to Atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/e1eb5d-ar-e1eb5d9.pkl. "
BLCA,17.0,0.862745098,inflamed,NR,"I have a female patient with bladder urothelial carcinoma whose tumor was assessed via nano-biopsy, including mRNA TPM analysis to evaluate the immune microenvironment. With a tumor mutational burden of 17.0, should we expect a favorable response to atezolizumab therapy?","I have a female patient with bladder urothelial carcinoma whose tumor was assessed via nano-biopsy, including mRNA TPM analysis to evaluate the immune microenvironment. With a tumor mutational burden of 17.0, should we expect a favorable response to atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/e3210d-ar-e3210d3.pkl. "
BLCA,,,,NR,"For a male patient with bladder urothelial carcinoma whose bladder biopsy revealed mRNA TPM expression (assessing the tumor immune microenvironment) and an indeterminate tumor mutational burden (TMB reported as ""nan""), how likely is he to benefit from treatment with atezolizumab?","For a male patient with bladder urothelial carcinoma whose bladder biopsy revealed mRNA TPM expression (assessing the tumor immune microenvironment) and an indeterminate tumor mutational burden (TMB reported as ""nan""), how likely is he to benefit from treatment with atezolizumab?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/e3d426-ar-e3d4266.pkl. "
BLCA,6.0,0.470588235,excluded,NR,"For a male patient with bladder urothelial carcinoma who has undergone mRNA TPM expression profiling of the tumor immune microenvironment and has a tumor mutational burden of 6.0, what is the likelihood that he will respond to Atezolizumab therapy?","For a male patient with bladder urothelial carcinoma who has undergone mRNA TPM expression profiling of the tumor immune microenvironment and has a tumor mutational burden of 6.0, what is the likelihood that he will respond to Atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/e41b1e-ar-e41b1e7.pkl. "
BLCA,9.0,2.176470588,desert,R,"I have a female patient with bladder urothelial carcinoma who has undergone mRNA TPM expression analysis from a bladder biopsy to assess her tumor immune microenvironment. With a tumor mutational burden of 9.0, would you consider her likely to benefit from Atezolizumab therapy?","I have a female patient with bladder urothelial carcinoma who has undergone mRNA TPM expression analysis from a bladder biopsy to assess her tumor immune microenvironment. With a tumor mutational burden of 9.0, would you consider her likely to benefit from Atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/e50d15-ar-e50d15f.pkl. "
BLCA,5.0,0.098039216,excluded,NR,"A female patient with bladder urothelial carcinoma has undergone mRNA TPM expression analysis from a kidney biopsy to assess her tumor immune microenvironment, and her tumor mutational burden is 5.0. Based on these factors, is she likely to respond to atezolizumab therapy?","A female patient with bladder urothelial carcinoma has undergone mRNA TPM expression analysis from a kidney biopsy to assess her tumor immune microenvironment, and her tumor mutational burden is 5.0. Based on these factors, is she likely to respond to atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/e56c96-ar-e56c96c.pkl. "
BLCA,5.0,0.274509804,excluded,NR,"In a patient with bladder urothelial carcinoma (BLCA) who underwent liver biopsy for mRNA TPM expression profiling of the tumor immune microenvironment and has a tumor mutational burden of 5.0, how likely is a positive response to atezolizumab therapy?","In a patient with bladder urothelial carcinoma (BLCA) who underwent liver biopsy for mRNA TPM expression profiling of the tumor immune microenvironment and has a tumor mutational burden of 5.0, how likely is a positive response to atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/e5bc41-ar-e5bc417.pkl. "
BLCA,,,desert,R,For a patient with bladder urothelial carcinoma whose bladder biopsy revealed mRNA TPM expression for immune microenvironment assessment—with tumor mutational burden data not available—would you expect a favorable response to atezolizumab therapy?,For a patient with bladder urothelial carcinoma whose bladder biopsy revealed mRNA TPM expression for immune microenvironment assessment—with tumor mutational burden data not available—would you expect a favorable response to atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/e71235-ar-e712352.pkl. 
BLCA,,,,NR,"I have a male patient with bladder urothelial carcinoma whose mRNA TPM expression was measured from a kidney biopsy to assess the tumor immune microenvironment. Although the tumor mutational burden data are unavailable, I am considering treatment with atezolizumab. Based on these factors, is this patient likely to respond favorably to the therapy?","I have a male patient with bladder urothelial carcinoma whose mRNA TPM expression was measured from a kidney biopsy to assess the tumor immune microenvironment. Although the tumor mutational burden data are unavailable, I am considering treatment with atezolizumab. Based on these factors, is this patient likely to respond favorably to the therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/e7bcab-ar-e7bcab0.pkl. "
BLCA,7.0,1.37254902,inflamed,NR,"I have a male patient with bladder urothelial carcinoma whose tumor immune microenvironment was evaluated via mRNA TPM expression analysis from a kidney biopsy, and his tumor mutational burden is 7.0 mutations per megabase. Considering these factors, is Atezolizumab likely to be an effective treatment option?","I have a male patient with bladder urothelial carcinoma whose tumor immune microenvironment was evaluated via mRNA TPM expression analysis from a kidney biopsy, and his tumor mutational burden is 7.0 mutations per megabase. Considering these factors, is Atezolizumab likely to be an effective treatment option?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/e7bf6c-ar-e7bf6c0.pkl. "
BLCA,1.0,0.196078431,inflamed,NR,"In a patient with bladder urothelial carcinoma evaluated via bladder biopsy for mRNA TPM expression and a tumor mutational burden of 1.0, would Atezolizumab likely be an effective treatment option?","In a patient with bladder urothelial carcinoma evaluated via bladder biopsy for mRNA TPM expression and a tumor mutational burden of 1.0, would Atezolizumab likely be an effective treatment option?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/e7e4f7-ar-e7e4f7c.pkl. "
BLCA,,,excluded,NR,"I have a male patient with bladder urothelial carcinoma who underwent mRNA TPM expression profiling from a bladder biopsy to assess the tumor immune microenvironment. The tumor mutational burden is reported as “nan.” Given these findings, can we expect a favorable response to Atezolizumab?","I have a male patient with bladder urothelial carcinoma who underwent mRNA TPM expression profiling from a bladder biopsy to assess the tumor immune microenvironment. The tumor mutational burden is reported as “nan.” Given these findings, can we expect a favorable response to Atezolizumab?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/e9475f-ar-e9475f7.pkl. "
BLCA,6.0,1.019607843,excluded,NR,"I have a male patient with bladder urothelial carcinoma. His biopsy was analyzed for mRNA TPM expression to evaluate the tumor immune microenvironment, and his tumor mutational burden is 6.0. Based on these factors, what is the likelihood that he will respond to atezolizumab therapy?","I have a male patient with bladder urothelial carcinoma. His biopsy was analyzed for mRNA TPM expression to evaluate the tumor immune microenvironment, and his tumor mutational burden is 6.0. Based on these factors, what is the likelihood that he will respond to atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/e94c30-ar-e94c30c.pkl. "
BLCA,3.0,0.705882353,excluded,NR,"In a female patient with bladder urothelial carcinoma who has had mRNA TPM expression profiling from a bladder biopsy and a tumor mutational burden of 3.0, how likely is it that she will respond favorably to atezolizumab therapy?","In a female patient with bladder urothelial carcinoma who has had mRNA TPM expression profiling from a bladder biopsy and a tumor mutational burden of 3.0, how likely is it that she will respond favorably to atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/e97af0-ar-e97af0f.pkl. "
BLCA,7.0,1.333333333,desert,NR,"In a male patient with bladder urothelial carcinoma, mRNA expression data (TPM) from a bladder biopsy was used to evaluate the tumor immune microenvironment, and the tumor mutational burden is 7.0. Given these factors, how likely is the patient to respond to Atezolizumab therapy?","In a male patient with bladder urothelial carcinoma, mRNA expression data (TPM) from a bladder biopsy was used to evaluate the tumor immune microenvironment, and the tumor mutational burden is 7.0. Given these factors, how likely is the patient to respond to Atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/e9ae8b-ar-e9ae8be.pkl. "
BLCA,14.0,2.764705882,inflamed,R,"How likely is a male patient with bladder urothelial carcinoma, who has a tumor mutational burden of 14.0 and an mRNA TPM expression profile from a bladder biopsy assessing the tumor immune microenvironment, to respond to Atezolizumab therapy?","How likely is a male patient with bladder urothelial carcinoma, who has a tumor mutational burden of 14.0 and an mRNA TPM expression profile from a bladder biopsy assessing the tumor immune microenvironment, to respond to Atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/eaa477-ar-eaa477a.pkl. "
BLCA,2.0,0.058823529,excluded,NR,"For a male patient with bladder urothelial carcinoma, where mRNA TPM expression was analyzed from a kidney biopsy to assess the tumor immune microenvironment and the tumor mutational burden is 2.0, what is the likelihood of a favorable response to atezolizumab therapy?","For a male patient with bladder urothelial carcinoma, where mRNA TPM expression was analyzed from a kidney biopsy to assess the tumor immune microenvironment and the tumor mutational burden is 2.0, what is the likelihood of a favorable response to atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/eb2962-ar-eb29625.pkl. "
BLCA,,,,NR,"Given that my patient with bladder urothelial carcinoma had mRNA TPM expression assessed from a bladder biopsy to evaluate the immune microenvironment and has an undefined tumor mutational burden, how likely is it that treatment with Atezolizumab will elicit a clinical response?","Given that my patient with bladder urothelial carcinoma had mRNA TPM expression assessed from a bladder biopsy to evaluate the immune microenvironment and has an undefined tumor mutational burden, how likely is it that treatment with Atezolizumab will elicit a clinical response?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/eb587a-ar-eb587a6.pkl. "
BLCA,,,,NR,"We have a male patient with bladder urothelial carcinoma whose mRNA TPM expression was evaluated from a lymph node biopsy to assess the tumor immune microenvironment, and the tumor mutational burden value is not available. Could you please help determine the likelihood of a response to Atezolizumab based on these findings?","We have a male patient with bladder urothelial carcinoma whose mRNA TPM expression was evaluated from a lymph node biopsy to assess the tumor immune microenvironment, and the tumor mutational burden value is not available. Could you please help determine the likelihood of a response to Atezolizumab based on these findings?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/ee3844-ar-ee3844c.pkl. "
BLCA,1.0,0.039215686,inflamed,NR,"In a male patient with bladder urothelial carcinoma (BLCA) who has a tumor mutational burden of 1.0 and mRNA TPM expression assessed from a lung biopsy to evaluate the tumor immune microenvironment, what is the likelihood of a favorable response to atezolizumab?","In a male patient with bladder urothelial carcinoma (BLCA) who has a tumor mutational burden of 1.0 and mRNA TPM expression assessed from a lung biopsy to evaluate the tumor immune microenvironment, what is the likelihood of a favorable response to atezolizumab?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/ef0e3d-ar-ef0e3d2.pkl. "
BLCA,14.0,,desert,NR,"In a patient with bladder urothelial carcinoma who has a tumor mutational burden of 14.0 and whose immune microenvironment has been evaluated via mRNA TPM expression from a ureter biopsy, how likely is a favorable response to treatment with atezolizumab?","In a patient with bladder urothelial carcinoma who has a tumor mutational burden of 14.0 and whose immune microenvironment has been evaluated via mRNA TPM expression from a ureter biopsy, how likely is a favorable response to treatment with atezolizumab?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/eff2ce-ar-eff2ce3.pkl. "
BLCA,14.0,1.098039216,inflamed,NR,"I have a patient with bladder urothelial carcinoma (BLCA) whose tumor immune microenvironment was evaluated via mRNA TPM expression from a kidney biopsy, and the tumor mutational burden is 14.0. Considering these factors, would you expect the patient to respond to Atezolizumab therapy?","I have a patient with bladder urothelial carcinoma (BLCA) whose tumor immune microenvironment was evaluated via mRNA TPM expression from a kidney biopsy, and the tumor mutational burden is 14.0. Considering these factors, would you expect the patient to respond to Atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/f20b82-ar-f20b827.pkl. "
BLCA,9.0,,excluded,R,"In a male patient with bladder urothelial carcinoma, mRNA TPM expression profiling from a bladder biopsy has been used to evaluate the tumor’s immune microenvironment, and his tumor mutational burden is measured at 9.0. Based on these findings, what is the likelihood that he will benefit from Atezolizumab therapy?","In a male patient with bladder urothelial carcinoma, mRNA TPM expression profiling from a bladder biopsy has been used to evaluate the tumor’s immune microenvironment, and his tumor mutational burden is measured at 9.0. Based on these findings, what is the likelihood that he will benefit from Atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/f275eb-ar-f275eb8.pkl. "
BLCA,8.0,,desert,NR,"In a male patient with bladder urothelial carcinoma who has undergone mRNA TPM expression analysis via bladder biopsy to assess the tumor immune microenvironment and exhibits a tumor mutational burden of 8.0, how likely is he to respond to atezolizumab therapy?","In a male patient with bladder urothelial carcinoma who has undergone mRNA TPM expression analysis via bladder biopsy to assess the tumor immune microenvironment and exhibits a tumor mutational burden of 8.0, how likely is he to respond to atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/f28c01-ar-f28c015.pkl. "
BLCA,7.0,0.803921569,desert,NR,"For a female patient with bladder urothelial carcinoma who has a tumor mutational burden of 7.0 and mRNA TPM expression data from a bladder biopsy, what is the likelihood of a favorable response to atezolizumab therapy?","For a female patient with bladder urothelial carcinoma who has a tumor mutational burden of 7.0 and mRNA TPM expression data from a bladder biopsy, what is the likelihood of a favorable response to atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/f2aae1-ar-f2aae14.pkl. "
BLCA,4.0,,excluded,NR,In a female patient with bladder urothelial carcinoma who underwent kidney biopsy for mRNA TPM expression analysis to evaluate the tumor immune microenvironment—and with a tumor mutational burden of 4.0—what is the likelihood of response to Atezolizumab therapy?,In a female patient with bladder urothelial carcinoma who underwent kidney biopsy for mRNA TPM expression analysis to evaluate the tumor immune microenvironment—and with a tumor mutational burden of 4.0—what is the likelihood of response to Atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/f3a9bc-ar-f3a9bce.pkl. 
BLCA,7.0,0.529411765,desert,NR,"In a male patient with bladder urothelial carcinoma who underwent a kidney biopsy for mRNA TPM expression analysis to assess the tumor immune microenvironment, and who has a tumor mutational burden (TMB) of 7.0, is there evidence to support a favorable response to atezolizumab therapy?","In a male patient with bladder urothelial carcinoma who underwent a kidney biopsy for mRNA TPM expression analysis to assess the tumor immune microenvironment, and who has a tumor mutational burden (TMB) of 7.0, is there evidence to support a favorable response to atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/f82bbd-ar-f82bbdc.pkl. "
BLCA,,5.921568627,inflamed,R,"I have a male patient with bladder urothelial carcinoma whose tumor biopsy was analyzed for mRNA TPM expression to evaluate the immune microenvironment, although his tumor mutational burden data are not available. Considering initiating Atezolizumab, what is the likelihood that he will respond to this therapy based on these findings?","I have a male patient with bladder urothelial carcinoma whose tumor biopsy was analyzed for mRNA TPM expression to evaluate the immune microenvironment, although his tumor mutational burden data are not available. Considering initiating Atezolizumab, what is the likelihood that he will respond to this therapy based on these findings?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/fb7aec-ar-fb7aec7.pkl. "
BLCA,5.0,,desert,NR,"I have a male patient with bladder urothelial carcinoma (BLCA) who underwent a bladder biopsy for mRNA TPM expression analysis to evaluate the tumor immune microenvironment, and his tumor mutational burden is 5.0. Based on these findings, is he likely to benefit from Atezolizumab treatment?","I have a male patient with bladder urothelial carcinoma (BLCA) who underwent a bladder biopsy for mRNA TPM expression analysis to evaluate the tumor immune microenvironment, and his tumor mutational burden is 5.0. Based on these findings, is he likely to benefit from Atezolizumab treatment?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/fd9476-ar-fd94761.pkl. "
BLCA,7.0,0.352941176,desert,NR,"In a female patient with bladder urothelial carcinoma, where a bladder biopsy has provided mRNA TPM expression data reflecting the tumor immune microenvironment and a tumor mutational burden of 7.0, how likely is it that she would respond favorably to treatment with atezolizumab?","In a female patient with bladder urothelial carcinoma, where a bladder biopsy has provided mRNA TPM expression data reflecting the tumor immune microenvironment and a tumor mutational burden of 7.0, how likely is it that she would respond favorably to treatment with atezolizumab?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/fed609-ar-fed6099.pkl. "
BLCA,10.0,,desert,R,"I have a male patient with bladder urothelial carcinoma who has a tumor mutational burden of 10. Additionally, we obtained mRNA TPM expression data from a separate biopsy to evaluate the tumor immune microenvironment. Considering these findings, would treatment with atezolizumab be appropriate for this patient?","I have a male patient with bladder urothelial carcinoma who has a tumor mutational burden of 10. Additionally, we obtained mRNA TPM expression data from a separate biopsy to evaluate the tumor immune microenvironment. Considering these findings, would treatment with atezolizumab be appropriate for this patient?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/ffa5c7-ar-ffa5c7c.pkl. "
